



plus

Makerere University / UVRI Centre of Excellence
for Infection and Immunity
Research and Training

Progress Report 2020



Front page pictures, clockwise from top left:

MUII-plus AGM and Symposium held in February 2020; MUII-plus fellow Pritch Kabaata volunteering at the COVID ward in Mulago; MUII-plus Group Leader and newly appointed Principal of Makerere University College of Health Sciences, Damalie Nakanjako handing over the office of Dean of Makerere Univeristy School of Medicine to fellow Group Leader, Annette Nakimuli.

Contents

Contents	2
Abbreviations.....	3
Summary.....	4
Acknowledgements	4
MUII-plus objectives.....	5
Aim 1. To promote Africa-relevant I&I scientific excellence [Scientific Quality].....	5
Aim 2. To provide career training for African I&I research leaders [Research Training].....	5
Aim 3. To utilise and enhance the UVRI-Makerere I&I research environment [Management & Environment]:	5
Aim 4. Engage in outreach [Citizenship]:	5
Aim 1. Promote Africa-relevant I&I scientific excellence	6
1.1 Developing the MUII Centre of Excellence	6
1.2 Recognition.....	6
Aim 2. Provide career training for African I&I research leaders [Research Training].....	6
2.1 Internships	6
2.2 Fellowships	7
2.3 Technical training	7
2.4 Mentorship and professional development.....	9
Aim 3. Utilise and enhance the UVRI-Makerere I&I research environment [Management & Environment].....	10
3.1 Research support.....	10
3.2 Research infrastructure	10
3.3 MUII-plus specific management progress	10
Aim 4. Engage in outreach [Citizenship]	10
4.1 Outreach in Science: MUII collaborative awards.....	11
4.2 Outreach in training.....	11
4.3 Outreach to the wider community and policy makers.....	11
Appendix 1. New grants reported by MUII Centre members and alumni: 2016-2020	13
Appendix 2. Publications by MUII Fellows, Alumni and Staff.....	26
Publications by MUII Fellows, Honorary Fellows, Alumni and Staff 2020.....	26
2019	30
Appendix 3. MUII fellows, past and present	47

Abbreviations

AESA	Alliance for Accelerating Excellence in Science in Africa	Impi	Implementation team (alluding to Zulu bands of warriors, impis)
AGM	Annual General Meeting	IRB	Institutional Review Board
ASBCB	African Society for Bioinformatics and Computational Biology	ISBC	International Society for Computational Biology
BBC	British Broadcasting Corporation	LANL	Los Alamos National Laboratory
BReCA	Nurturing Genomics and Bioinformatics Research Capacity in Africa	LSHTM	London School of Hygiene & Tropical Medicine
ChAd	Chimpanzee Adenovirus	LUMC	Leiden University Medical Centre
CHIM	Controlled Human Infection Model	MNRH	Maternal, Neonatal and Reproductive Health
CKD	Chronic kidney disease	MRC	Medical Research Council
CHS	College of Health Sciences (Makerere)	MUII-plus	Makerere University – Uganda Virus Research Institute Centre of Excellence for Infection and Immunity Research and Training
CONAS	College of Health Sciences		
COVAB	College of Veterinary Medicine, Animal Resources and Biosecurity (Makerere)		
DELTAS Africa	Developing Excellence in Leadership, Training and Science Africa	MVA	Modified Vaccinia virus Ankara
DfID	Department for International Development	NCD	Non-communicable disease
EANBIT	Eastern Africa Network for Bioinformatics Training	NCE	No Cost Extension
eGFR	Estimated glomerular filtration rate	PWD	People with disabilities
GSK	GlaxoSmithKline	QC	Quality control
GWAS	Genome wide association study	SVAR	School of Veterinary Medicine and Animal Resources
IACUC	Institutional Animal Care and Use Committee	UMIC	Uganda Medical Informatics Centre
IDI	Infectious Diseases Institute	UVRI	Uganda Virus Research Institute

Summary

The Makerere University-Uganda Virus Research Institute (UVRI) programme on Infection & Immunity research (MUII) has been in existence more than 12 years, training African scientists to harness laboratory and computational skills to address the continent's major health challenges. We have so far supported 64 fellowships: 50 fully MUII-funded (3 group leaders, 15 post-docs, 17 PhD fellows, and 15 Masters fellows) and 14 honorary fellows (10 PhD and 4 Masters fellows). Alumni include leading academics in human and veterinary medicine and research at UVRI and Makerere University.

This report focusses on achievements of MUII-plus in 2020.

The COVID-Pandemic, as for the rest of the world, has affected our progress in both positive and negative ways. A notable achievement is the securing of new research funding in 2020: MUII-plus Centre members (PI, staff, alumni, fellows and honorary fellows) together contributed to securing over USD 14,700,000 in research funds, of which approximately USD 2,880,139 was won by MUII-plus fellows. MUII fellows, alumni and staff together have published 81 papers, of which 27 articles were specifically attributed to MUII-plus.

The MUII-plus training programme has continued to build career profiles of young bright students equipped with skills to work in different career paths. Three of our current fellows submitted their theses and hope to graduate in 2021. A former Masters' student was awarded a PhD scholarship at Leiden University.

The fellowship programme is complemented by courses and workshops to provide specific skills, and to support professional development: five online courses and workshops were held in 2020.

In outreach activities, our fellows and staff participated in a number of COVID-19 community engagement activities such as AAS-funded study on COVID-19 management in markets in Kampala.

Among special achievements, MUII-plus group leader Annettee Nakimuli has been appointed Dean of Makerere's School of Medicine, and Damalie Nakanjako as Principal of the Makerere University College of Health Sciences.

Acknowledgements

MUII-plus is supported through the DELTAS Africa Initiative (Developing Excellence in Leadership, Training and Science Africa; Grant no. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESA), and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant no. 107743) and the UK Government.

Grants from the Royal Society, the European and Developing Countries Clinical Trials Partnership, the Wellcome Trust, the Bill and Melinda Gates Foundation, the National Institutes of Health of the United States of America (including the Fogarty foundation), the European Union, Grand Challenges Canada, the Royal Society of Tropical Medicine & Hygiene, the European Academy of Allergy and Clinical Immunology, the Makerere University Nurture Program, GlaxoSmithKline, the Alliance for Global Health and Science at the University of California, Berkeley, USA, the Wheeler Center for Emerging and Neglected Diseases, University of California, Berkeley, USA, the Open Philanthropy Project Fund (an advised fund of Silicon Valley Community Foundation, USA) and the United Kingdom's Medical Research Council also contribute to the achievements of the MUII Centre members.

We thank you for your support, and hope you will enjoy reading about our progress.

MUII-plus objectives

Our goal as the Makerere University – UVRI Centre of Excellence for Infection and Immunity research and training (MUII-plus) is to drive Africa-relevant Infection and Immunity (I&I) science in Uganda by bringing together scientists from the foremost health research institute (the Uganda Virus Research Institute, UVRI), and foremost university (Makerere), with their world-class, external collaborators, to support excellence in I&I research and training.

Our “Vision 2040” is Africa leading advances in Infection and Immunity research, with transformative impact on African health.

Our specific aims align with DELTAS Africa’s strategy [shown in square brackets]. MUII-plus aims, as set out in our proposal, are as follows.

Aim 1. To promote Africa-relevant I&I scientific excellence [*Scientific Quality*].

Transitioning from the MUII training programme, the MUII-plus Centre of Excellence comprises senior Ugandan I&I scientists and young, emerging leaders, their research groups, trainees, and international collaborators: a mutually-supportive platform for world-class Africa-relevant science and training.

Aim 2. To provide career training for African I&I research leaders [*Research Training*]

Strategies include

- Career-pathway fellowships: Uganda-based, with international collaboration and co-supervision
- Focus on bioinformatics: ring-fenced bioinformatics fellowships and project grants; short courses integrated with partner-network opportunities
- Focus on emerging & re-emerging infectious diseases: ring-fenced PhD opportunities at College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB)
- Improved efficiency and quality in I&I Masters training: coordination of courses across Makerere colleges; expert input from Uganda partners, and video-conferencing from Cambridge
- Professional development and citizenship: mentored leadership experience; curriculum of workshops
- Planning for sustainability and succession

Aim 3. To utilise and enhance the UVRI-Makerere I&I research environment [*Management & Environment*]:

- Drive research in new laboratories developed during phase 1 (MUII-1), in new COVAB Biosecurity laboratories, in the MRC-funded Uganda Medical Informatics Centre
- Strengthen research support at lead institution, UVRI

Aim 4. Engage in outreach [*Citizenship*]:

Develop communication skills; raise public awareness, network scientists and trainees, share resources and research findings, interact with policy makers, promote research implementation.

Aim 1. Promote Africa-relevant I&I scientific excellence

1.1 Developing the MUII Centre of Excellence

MUII-plus has continued to attract like minds to fostering collaborations and networks of Uganda's best scientists in the infection immunity unity research. Our centre membership now stands at 110 Uganda-based members and international partners. Our story on MUII successes in career development over the last decade was published in AAS Open Research and the video is uploaded on you tube: <https://youtu.be/ZhzWnJbIQFI>.

MUII AGM and Symposium. We held a successful AGM and symposium in February, fortunately ahead of the impact of the COVID-19 pandemic. We interacted with the local and international researchers, key policy makers, and potential MUII-3 partners. The meeting focussed on building partnerships and collaborations for science research: we were fortunate to host potential partners from Sierra Leone and Cameroon, among others. We as well hosted policy makers and interacted with representatives from the private sector. MUII fellows shared and disseminated science in plenary and breakout sessions mentored by both local and international supervisors and partners.

Scientific meetings and seminars After the AGM, face-to-face seminars were discontinued due to COVID-19-related restrictions, but online opportunities were continued and shared

Funding. Our fellows, alumni and members have together secured approximately USD 14,726,393 in research funds in 2020. The fellows contributed approximately USD 2,880,139 to this total. Special congratulations to Annetee Nakimuli who won a Flair fellowship by the Royal Society & African Academy of Sciences worth USD 407,280 and Segun Fatumo who won a Wellcome Intermediate Research Fellowships. A list of the grants won by our current fellows and alumni is appended.

Publications. MUII fellows, staff and alumni have published 81 papers in 2020, of these 27 acknowledged MUII-plus.

1.2 Recognition

Congratulations to MUII-plus group leaders Annetee Nakimuli, who was appointed Dean of the School of Medicine at Makerere, and Damalie Nakanjako, who was appointed Principal of the Makerere University College of Health Sciences.

Highlight. We developed three new, science-focused theme groupings in preparation for DELTAS-2 and Key Question (KQ) leaders were appointed, together with senior advisors. These teams contributed to the MUII-3 application development and are already working together on new challenges, including the national COVID-19 response and further funding applications.

Aim 2. Provide career training for African I&I research leaders [*Research Training*]

2.1 Internships

In our internship programme, we placed 56 general interns (27 males and 29 females). We recruited one person with disability (PwD) in the laboratories and one strategic intern in the area of genetic epidemiology under the supervision of our bioinformatics fellow Segun Fatumo. Due to the pandemic, we received fewer than usual internship applications, and placed applicants only if this could be done safely.

One of our previous strategic interns went on to full employment with the MRC/UVRI and LSHTM Uganda Research Unit in Masaka.

2.2 Fellowships

Details of all fellows are listed in Appendix 3.

2.2.1 Completed fellowships One of our two remaining MMED fellows defended his thesis and hopes to graduate in 2021; the remaining MMED fellow has been delayed due to COVID-19 but is on track to complete in 2021. One of our Masters' fellows from the first cohort, Emmanuella Druciru was awarded a PhD scholarship at Leiden University! The MUII-BRecA Masters fellows in bioinformatics successfully finished their first year and are progressing well. Four of our remaining 9 PhD fellows have submitted their theses and hope to graduate in March 2021. The remaining 5 (fully-funded by MUII-plus) have clear plans for completion during the NCE.

2.2.2 Continuing fellowships. Our fellows have been delayed in one way or another by the Pandemic. We however have continued monitoring their progress and completion at the electronically held quarterly fellows' meetings. We have also continued to ensure quality research and compliance with good clinical research practice through internal monitoring while observing COVID-19 regulations and recommendations: most of our fellows have had their study close out monitoring visits. Our positive experience of continuous study monitoring was published in the AAS Open Research. The article is accessed at <https://aasopenresearch.org/articles/3-57/v1>.

With our subscription to plagiarism software, we have run all our fellows' theses before submission for defence.

2.3 Technical training

In parallel with the fellowship programme, MUII-plus supports technical training in key areas through the work of the Statistics, Immunology and Bioinformatics Implementation teams (Impis).

2.3.1 Statistics Andrew Abaasa replaced Rebecca Nsubuga to lead the statistics impi. The impi had planned for face to face teaching and practical epidemiological and statistical sessions, however this was not achieved and hope to have the courses online this year.

2.3.2 The Immunology Impi contributes to immunology training at Makerere University. Our alumnus, Rose Nabatanzi accepted to take on leadership of the impi from Steve Cose and Bernard Bagaya who have done a tremendous job at both Makerere University and UVRI to promote immunology training in the country. Activities include support to the new Department of Immunology & Molecular Biology (approved by University Council in March 2016) and the Master of Science in Immunology and Clinical Microbiology at the Makerere University College of Health Sciences, and plans for a Ugandan Immunological Society.

2.3.3 Cambridge seminars We have been fortunate to have world renowned scientists and mentors in Immunology give their time to Masters in Immunology and Clinical Microbiology (MICM) and Masters in Bioinformatics (MSBT) students, through the online seminars organised by the Cambridge –Africa team at the University of Cambridge. The feedback from students indicates that the seminars are the highlight of each week. A blog highlighting the success of the seminars was published at <https://www.cambridge-africa.cam.ac.uk/cambridge-africa-updates/a-new-generation-of-immunologists-for-africa>. Each year, 8 video seminars are scheduled. We held 5 before the lock down and hope to resume this year, as highlighted in the brochure. We held 5 of the 8 scheduled seminars before the pandemic and hope to resume this year. Cambridge also supported students to attend the online meeting of the British Society for Immunology, and this was a great success also.

Fig 1: Cambridge Seminar Schedule, 2019-2020

 		
Makerere-Cambridge video linked Seminar Series		
2019-20 14.00 - 16.00 EAT		
Date	Speaker	Title
Wednesday 29 th January	Dr Nick Holmes	Flow cytometry
Wednesday 5 th February	Dr Soumya Banerjee	Computational immunology
Wednesday 4 th March	Dr Lucy Weinert	Phylogenetics and epidemiological inferences from trees
Wednesday 11 th March	Professor Julian Rayner	Malaria parasite biology, immunology and the search for a highly effective vaccine
Wednesday 18 th March	Dr Stephen Graham	Protein degradation as a mechanism of viral immune evasion
Wednesday 25 th March	Professor Julian Parkhill	Emergence, transmission and evolution of bacterial pathogens - how genomics and phylogenetics can inform our understanding of pathogen spread
Wednesday 1 st April	Professor Clare Bryant	Host recognition of bacterial infections through pattern recognition receptors
Wednesday 22 nd April	Dr James Whitehorn	Antimicrobial resistance

2.3.4 **The Bioinformatics and Computational Biology (BCB) Impi** is led by alumni Jonathan Kayondo and Deogratius Ssemwanga, together with John Kitayimbwa, Daudi Jingo, David Kateete and Mathew Cotten. This year's activities include the following.

Bioinformatics Courses: An Intermediate Bioinformatics course (Intermediate IBT-2020) on 16S rRNA NGS -based Microbiome data analysis was run. This is an H3ABioNet 2 month 2-day (4 hours/day of contact time per week) on-line course series with the BCB hosting a local class and providing teaching assistance support. Course modules include Linux/R programming, Study design, Bioinformatics 16S rRNA analysis pipelines among others. UVRI class had 4 enrolled students (2 females/ 2 males) supported by on-site Teaching Assistants flexibly whenever need arose.

Advanced Bioinformatics course on viral bioinformatics and genomics. The 2020 course was not held due to COVID-19.

Mentorship: Mr. Trevor Mugoya, the 2019 Strategic bioinformatics intern, has received BCB mentorship. He is involved in the establishment of bioinformatics vector genomics pipeline at UVRI. Although COVID-19 has complicated his program we have found a way to continue it remotely. We have continued mentoring/ co-supervising our 3 research fellows (Alfred Ssekagiri, Phiona Tushabe and Prossy Namuwulya) at UVRI. They are now in their 2nd year of the GeMVi PhD fellowship. Dr. Jonathan Kayondo and Professor Matthew Cotten hosted and co-supervised Mr. Henrick Aduda Kola, an EANBiT training fellow, at UVRI for his M.Sc. research project. He is working on final edits before his thesis submission.

Drs. Jingo and Kayondo are supervising and mentoring a number of BReCA M.Sc. fellows. Mr. Edward Lukyamuzi is a MUII-co-funded, UVRI BReCA fellow under hub supervision.

Bioinformatics Capacity for Technical support for Fellows/Projects at UVRI-: We passed the H3ABioNet 16S rRNA microbiome sequence data analysis accreditation for site competence in this area. We demonstrated expertise and availability of computational infrastructure for this work at the UVRI BCB.

We have continued to maintain the established 16S rRNA analysis pipelines and workflows at UVRI.

Networking: Fogarty training grants- BCB members continued providing teaching support to BReCA and EANBiT programs. Alfred Sekagiri and Daudi Jjingo supported the EANBiT Residential bioinformatics course, whereas Ssekagiri, Jjingo, Kayondo, Nabaakoza, and Bbossa are teaching modules for the BReCA M.Sc. program. Semester 2 courses are still running, after COVID-19 delays.

GeMVi - NIHR Global Health Research Group project on the Application of Genomics and Modelling to the Control of Virus Pathogens (GeMVi) in East Africa.

H3ABioNet- BCB has continued working with H3ABioNet to advance bioinformatics capacity at UVRI (see intermediate bioinformatics course, curricular development, and node accreditation exercise above).

MRC/University of Glasgow CVR - UVRI collaboration was mostly in the COVID-19 genomics.

BCB members, Daudi Jjingo, Jonathan Kayondo, Deogratious Ssemwanga have applied to a number of funding opportunities including-the BMGF grand challenges explorations, the NIH Emerging Infectious Diseases Research Centers, Data Science – Initiative Africa Research Hubs, Data Science- Initiative Africa Training Centers, Data Science-Initiative Africa Open Data and Coordinating Centers among others.

2.4 Mentorship and professional development

Fig 2: A mentorship session at the February AGM



The MUII mentorship programme continues to thrive and support our fellows to identify mentors in their different research areas. The team were actively engaged in the 2020 AGM where they teamed up eleven speed dating pairs for mentorship sessions. All the mentors and mentees gave very positive feedback on how these sessions were very useful.

The MUII mentorship portal was added to the MUII-plus website and different profiles for mentee, mentee/mentors, and mentors were added.

Findings of the baseline survey were published in the AAS Open Research journal: *“Analysis of the MUII-plus Mentorship Programme: Reflections of Fellows’ Experiences and Lessons for Other Programmes.* The publication can be accessed at <https://aasopenresearch.org/articles/3-37/v1>

The fellowship programme is complemented by skills and professional development workshops. In partnership UVRI, IDI and MRC, the fellows were hosted to a number of online trainings and

workshops in 2020. (Table 1).

Table 1: MUII-plus online workshops and courses held in 2020

Workshop/course
Good clinical practice
Training on working from home
GO skills training
Qualitative data analysis using the NVIVO software

Aim 3. Utilise and enhance the UVRI-Makerere I&I research environment [*Management & Environment*]

MUII-plus aims to build on the achievements of MUII-1 to enhance research infrastructure at the Ugandan partner institutions, and to enhance research support, particularly at UVRI where the grant is held.

3.1 Research support.

MUII-plus continues to strengthen research support at lead institution, UVRI, contributing to research support staff at UVRI in several areas: Finance, Information Technology, Human Resources, Procurement and Internal Audit. All the staff have utilised their career development grants to enrol for various courses and workshops. For example, our Centre Manager undertook Leadership training with a University of Washington programme managed locally at the IDI. Our Accountant was awarded extra funds to complete his PhD while the Internal Monitor was awarded a top up grant to pursue her masters at the London School of Hygiene and Tropical Medicine.

3.2 Research infrastructure

Our plans for infrastructure were to drive research in the completed and renovated laboratories including the UVRI immunology training lab, the new CoVAB Biosecurity laboratories, and the Bioinformatics and computational Biology Lab at CONAS.

All the planned renovation work on the Laboratories including the UVRI training lab, the COVAB Lab and the CONAS lab were completed and all laboratories are in use.

3.3 MUII-plus specific management progress

MUII-specific management activities have progressed smoothly despite the Pandemic. We drafted two policy documents; steps for business continuity during the Pandemic and guidelines for working from home during the Pandemic.

3.3.1 **An external audit** was conducted for 2019.

3.3.2 **Administrative meetings** were held bi-weekly, chaired by the Centre Manager. These were held online on zoom to observe the COVID-19 regulations.

3.3.3 **Executive meetings** were held quarterly, chaired by the Centre Director.

3.3.4 **Steering Committee meetings** have been held twice, in January and August 2020.

3.3.5 **A No Cost Extension** was awarded until September 2021.

Aim 4. Engage in outreach [*Citizenship*]

MUII-plus aims to promote Infection and Immunity research in Uganda and the region through outreach in three areas: (i) in science, to regional and international collaborators, (ii) in training to regional centres of excellence and (iii) to the wider community to share the excitement and importance of science for the community, and to promote translation of research results.

4.1 Outreach in Science: MUII collaborative awards

In 2020, we initiated new collaborations with University of Makeni in Sierra Leone, Centre de Recherche sur les Maladies Emergentes et Reemergentes (CREMER) in Cameroon and the Uganda Christian University in Uganda. The partners were able to attend our February AGM and establish strong relationships which were further developed through Zoom meetings in proposal development.

Led by DELTAS programme SANTHE we applied successfully with colleagues from IDeAL and Afrique One for funding for a collaborative consortium on Monitoring and Evaluation. This collaboration is in progress.

Travel for our remaining fellows and travel awardees was put on hold, but we hope that it will be possible for the proposed trips to be undertaken during the NCE.

Fig 3: New Collaborations with Dr Marcel Tongo, CREMER in Cameroon



4.2 Outreach in training

The Immunology in the Tropics short course took place in Gabon between Jan 13-18, 2020 and was attended by 50 participants.

A number of MUII-plus fellows have availed their expertise for COVID-19 response such as participating in SARSCoV-2 testing and phylogenetics; and in modelling the dynamics of COVID-19 Epidemic in Uganda, exploring the implications for national mitigation measures. MUII is supporting the Makerere University Biomedical Research Centre to conduct laboratory training for detection of SARS-COV-2 and related pathogens to strengthen Uganda's rapid response to COVID-19 and other epidemics/pandemics in the future. This work is being led by MUII-plus alumnus David Kateete.

4.3 Outreach to the wider community and policy makers

Our AGM included presentations from, and discussion with, stakeholders and implementation partners including the chair of the parliamentary committee on health, the CEO of CIPLA Uganda, and colleagues from the Aga Khan Foundation.

MUII-plus staff (Fiona Luboga and Mary Gorrethy Mboowa) participated in collection of data on conversations taking place on social media/radio/television, to understand the public response to the COVID-19 lockdown.

Our communication team, with funding from AAS conducted a three month's public engagement campaign in 5 markets in Kampala metropolitan area, targeting 150,000 market vendors. As part of the engagement, researchers interacted with the market vendors and share scientifically proven information about SARS-CoV- 2 infection prevention and control. The engagement resulted in collaborative message development by both the markets vendors and researchers. The messages were translated into materials such as banners and video clips in Luganda, the most widely spoken dialect in the project area and were shared on social media. MUII-Alumni Agnes Kiragga, John Kitayimbwa, and Ronald Galiwango produced two policy briefs; one describing the Ugandan epidemic and implications for control and the second, cautioning the exclusive use of face masks. These study results have been embraced by the national COVID-19 task-force at the Ministry of Health, Government of Uganda and results will be published in scientific journals.

Fig 4: MUII-plus fellow Saudah Namubiru interacting with market vendors



Appendix 1. New grants reported by MUI Centre members and alumni: 2016-2020

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
MUII-plus fellows					
NURTURE research training fellowship. PI Nelson Sewankambo	Annettee Nakimuli (PI)	Makerere University; University of Cambridge	Makerere University - NURTURE Program.	£45,800	2016-2018
Cambridge Africa – Alborada Research fund	Carmel McNiery (PI), Annettee Nakimuli (Co-PI)	Makerere University; University of Cambridge	Wellcome Trust – Cambridge Centre for Global Health Research	£10,400	2016-2018
Bill & Melinda Gates Foundation	Annettee Nakimuli (Travel awardee)		Travel award to attend the Deep Dive workshop of the Maternal, Newborn and Child Health Program, Seattle, USA	Travel and accommodation	Sep-17
Keystone Symposia Global Health Travel Award	Annettee Nakimuli (Travel awardee)		Keystone Symposia	\$2,960 USD	Oct-17
Development grant MR R015031: Holistic Approach To Unravel Antibacterial resistance in East Africa (HATUA)	Matt Holden (PI) Benon Asimwe (co-PI)	St Andrews University Makerere University CHS	MRC UK	£80,000	2017-2018
NK cells and ART	Damalie Nakanjako (PI)	Makerere University CHS	Alliance for Global Health and Science at the University of California, Berkeley, USA and the Wheeler Center for Emerging and Neglected Diseases, University of California, Berkeley, USA.	\$35,000	2017-2018

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
IUIS-FAIS Immuno-Ethiopia 2017 Travel Award A course: “New developments in the immunology, diagnosis and treatment of cutaneous and visceral leishmaniasis, schistosomiasis and helminth infections in an area of high tuberculosis prevalence”	Moses Egesa (Travel awardee)	UVRI	Sponsored by: The International Union of Immunological Societies, the University of Gondar, Ethiopia and the University of Lausanne, Switzerland.	Travel and accommodation, in kind	2017
Vaccinology Course Bursary: Vaccinology in Africa Course	Moses Egesa (Bursary Awardee)	UVRI	Jenner Institute, University of Oxford and MUII Plus	Fees and accommodation, in kind	2017
American Society for Tropical Medicine & Hygiene Travel Award	Richard Sanya (Travel awardee)	UVRI	American Society for Tropical Medicine & Hygiene	Fees, accommodation, travel costs, in kind	2017
IAS travel scholarship	Rose Nabatanzi (Travel awardee)	Makerere CHS	International AIDS Society	Fees, accommodation, travel costs, in kind	2017
Keystone travel scholarship	Rose Nabatanzi (Travel awardee)	Makerere CHS	Keystone Symposia	Fees, accommodation, travel costs, in kind	2017
Nurturing Genomics and Bioinformatics Research Capacity in Africa (BReCA)	David Kateete (PI) Daudi Jingo (PI) Graham Mardon (PI)	Makerere University; Baylor College of Medicine	NIH Fogarty	\$1,250,000	2017-2021
Investigating the role of altered Lung microbiome in the pathogenesis of HIV associated COPD	Alex Kayongo (PI)	Makerere CHS	GSK NCD open lab	£100,000	2017-2020
Cardiovascular health after pre-eclampsia	Annettee Nakimuli (PI)	Makerere University CHS	GSK NCD-Open lab	£100,000	2018-2020

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Using <i>in vitro</i> mycobacterial growth inhibition assays as a tool to assess functional immune responses induced by VPM1002 vaccination in infants	Simon Kimuda (PI)	MRC/UVRI	MRC (IMPRINT vaccine network)	£63,500	2018-2019
Holistic Approach To Unravel Antibacterial resistance in East Africa (HATUA)	Matt Holden (PI; MUII+ collaborator) and Benon Asimwe (co-PI; MUII+ Group Leader)	Makerere University; UVRI; University of St Andrews	MRC UK	£2,995,000	2018-2022
The Role of Transcription Profiles in Assessing Host and Treatment Responses in Type 2 Diabetes Mellitus and Tuberculosis Infection	Irene Biraro	Makerere University; UVRI	MRC/UVRI and LSHTM Uganda Research Unit post-doctoral fellowship	£39,825	2018-2020
Assessing functional immune responses induced by ChAdOx1 85A-MVA85A prime boost vaccination in BCG vaccinated adolescents from Uganda	Simon Kimuda	UVRI	MRC/UVRI and LSHTM Uganda Research Unit post-doctoral fellowship	£34,465	2018-2019
Preparing for <i>Schistosoma mansoni</i> controlled human infection studies in Uganda	Meta Roestenberg (PI) MosesEgesa; Alison Elliott	UVRI; Leiden University Medical Centre	Medical Research Council UK via the HIC-Vac network	£89,563	2018-2019
Clinical evaluation of novel plasma biomarkers for stage diagnosis among sleeping sickness patients in Uganda	Charles Kato Drago (PI)	Makerere University	EDCTP	€130,125	2019-2022
Supplementary funds to complement the MUII PhD fellowship support	Lois Bayigga	Makerere University; Boston	NIH Fogarty International Center	\$44,345	2018
MIDAS (Models of Infectious Disease Agents Study)	John Kitayimbwa	Makerere University; Edinburgh University	NIH	\$10,000	2019

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
CG259 /UGA-AVE-17-107	Denis Muhanguzi (PI)	Makerere University	GALVmed	\$52,254.8	2017-2018
ROSLIN 2006	Denis Muhanguzi (PI)	Makerere University	The Roslin Institute and Royal (Dick) School of Veterinary Sciences	\$23,760	2017-2018
Role of Gut microbiome in Prostate cancer Pathogenesis	Paul Katongole (PhD student)	Makerere University	Uganda Cancer Institute	1.Tuition	2018-2021
			(African Development Bank – Fund)	2. Stipend	
				3. Research costs	
				(\$30,000)	
Exploring the feasibility of a population cohort to facilitate long-term studies on risk factors for non-communicable diseases in Uganda.	Annettee Nakimuli	Makerere University	Makerere University-Research and Innovative Fund	\$51,181	2019 - 2020
Advancing Tissue and Organ Biobanking in Uganda	Annettee Nakimuli	Makerere University	Makerere University-Research and Innovative Fund	\$66,139	2019 - 2020
WSI International fellowship	Annettee Nakimuli	Makerere University	Wellcome Trust Sanger Institute (WSI)	\$130,029	2019 – 2021
Use of Machine Learning as a Prognosis Prediction Model to Guide Clinical Decision Making on the Infectious Diseases Unit at Kiruddu National Referral Hospital	Irene Biraro PI Damalie Nakanjako (co-PI)	Makerere University	Makerere University-Research and Innovative Fund	\$13,458	2019 - 2020
Pregnancy Associated Tuberculosis (PAT): Immunological Outcomes of Exposed Newborns Study	Irene Andia	Makerere University	CRICK African Network	\$188,541	2019 - 2021

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Towards Elimination of Rhodesiense Human African Trypanosomiasis: Spatial and temporal mapping of disease hotspots in Uganda.	Drago Charles Kato	Makerere University	CARTA	\$48,000	2019 - 2020
Cytokines as novel therapeutic agents in the management of late stage Trypanosoma brucei rhodesiense sleeping sickness: a preclinical trial (CaNTMS)	Drago Charles Kato	Makerere University	Makerere University	\$21,602	2019 - 2020
African Research Collaboration on Sepsis (ARCS)	Pritch Kabaata (MMed)	Makerere University/ UVRI	National Institute of Health Research in the United Kingdom	\$5,000	2019
Role of glycan-specific antibodies	Simon Kimuda Post-doc	MRC/UVRI	Crick African Network	\$188,541	2019 - 2021
CCHF outbreak investigation in Lyantonde for a duration of a month (Public engagement activity)	Stella Atim (PhD)	MUK/UVRI	Centre of Virus Research (CVR), University of Glasgow	\$2,601	2019
BRecA PhD training fellowship	Alfred Sekagiri	Makerere University	Makerere University	\$53,000	2019 - 2022
GEMVI Research Fellowship	Alfred Sekagiri	Makerere University	Kenya Medical Research Institute	\$13,150	2019 - 2020
Use of Mobile-phone based patient follow up to promote social distancing during COVID19 pandemic	Damalie Nakanjako PI	School of Medicine NITA Uganda Makerere Joint AIDS Program	Makerere University-Research and Innovative Fund	\$16,337.69	2020-2021
Use of a four pronged approach to improve ART initiation rates at Kiruddu Referral Hospital	Damalie Nakanjako PI		Makerere University-Research and Innovative Fund	\$43,243	2020-2021
Capacity building for Vaccine Research in Africa	Damalie Nakanjako PI	Makerere University Universities of Nairobi, Rwanda, Dar es salaam, Addis Ababa	Association of Research Universities in Africa (ARUA)	\$500,000	2020-2022

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
CARE: COVID-19 and Antimicrobial Resistance in East-Africa – impact and response	Benon Asimwe (PI)	HATUA Consortium with the UK partner at University of St. Andrews	DHSC/UKRI Global Effort on COVID-19 (GECO) Health Research	\$1,343,060	2020
Respiratory Coinfections and Microbiome in COVID-19: Prevalence & Implications	David Patrick Kateete (PI)	Makerere University	AAS COVID-19 response	\$200,000	2020-21
Disentangling the population structure of MRSA in an urban low-income setting	David Patrick Kateete (PI)	Makerere University	Cambridge-Africa ALBORADA Research Fund, Africa	\$23,000	2020
To investigate the relationship between microbial diversity and pulmonary TB disease, in a setting with high burden of HIV and TB coinfectionKampala, Uganda	David Patrick Kateete (PI)	Makerere University	European and Developing Countries Clinical Trials Partnership EDCTP	\$180,000	2020-22
FLAIR fellowship	Annettee Nakimuli (PI)	Makerere University	Royal Society and African Academy of Sciences	\$407,280	2020-22
Grand Challenges Africa	Annettee Nakimuli (PI)	Makerere University	African Academy of Sciences	\$100,000	2021-22
PhD Research funds	Nassanga Beatrice (Fellowship)	MRC/UVRI and LSHTM Uganda Research Unit	MRC/LSHTM	\$36,689	2020-2021
The role of antimalarial antibodies in functional modulation of the natural killer cell response to malaria infection	Stephen Tukwasibwe (Fellowship)	International Center of Excellence in Malaria Research (ICEMR)	NIH	\$49,900	2020-2022
HIV and co-infections in Uganda." capacity-building grant (Post doctorate)	Rose Nabatanzi-Magala (fellow)	IDI	Fogarty International Center, National Institutes of Health	\$8,000	2020-2022

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Characterisation of the latent reservoir among HIV infected individuals on long term treatment	Rose Nabatanzi Magala		EDCTP	\$180,891	2020-2023
Postdoctoral fellowship Targeting Domestic Animals and tsetse fly vectors to control nagana and accelerate elimination of acute sleeping sickness from hotspot villages of Eastern Uganda	Muhanguzi Denis (PI)		Carnegie Corporation of New York	\$35,800	2020-2022
Development of Indirect Enzyme Linked Immunosorbent Assay [ELISA] for (SARS-COV-2) Surveillance in Uganda	Muhanguzi Denis (Co-PI)		PRESIDE, MoSTI, Government of Uganda	\$107,309	2020-2021
Enhancing Institutional Capacity for Ethical Conduct of Research Involving Animals (ICEcoRIA)"	Muhanguzi Denis (Co-PI)	Makerere University	Government of Uganda	\$33,219	2020-21
MaKRIF Accelerating anti-tick vaccine development using computational methods	Muhanguzi Denis (PI)	Makerere University	Government of Uganda	\$20,336	2020-21
Benchmarking seroprevalence and economic importance of key livestock diseases in Karamoja	Muhanguzi Denis (PI)	Makerere University	Mercy Corps USAID	\$156,897	2020-2021
Vectoclor Field trial	Muhanguzi Denis (PI)		Ceva Santé Animale	\$46,826	2020-21
Gilead Research Fund supplementary funding	Kabata Pritch (Fellow)	IDI	Infectious Disease Institute	\$2,600	2020

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infection in Patients with Diabetes Mellitus:	Irene Andia	Makerere University	European and Developing Countries Clinical Trials Partnership (EDCTP)	\$5,322,280	2020 - 2025
Presidential Scientific initiative on epidemics	Kato Drago(PI) Nixon Niyonzi ma Enock Matovu Emmanuel Othieno Ssebugere Patrick	Makerere University	Government of Uganda	\$453,473	2020
Presidential Scientific initiative on epidemics	Enock Matovu (PI) Charles Kato D (co-investigator) Monica Namayanja	Makerere University	Government of Uganda	\$595,494	2020
Presidential Scientific initiative on epidemics	John Baptist (PI) Kato Charles D (co-investigator) Edward Wampande	Makerere University	Government of Uganda	\$767,154	2020
	Kato Charles D (PI) Ssekatawa Kenneth	Makerere University	WHO/TDR	\$15,000	2020
EDCTP Career Development Fellowship	Kato Charles D (PI)	Makerere University	EDCTP	\$158,375	2020
Glycan and protein specific antibody functionality in schistosomiasis immunity	Egesa Moses (Co-nvestigator) PI: Dr Anna M. O. Kildemoes	MRC/UVRI and LSHTM Uganda Research Unit , Department of Parasitology, LUMC , University of Oxford (UOx)	HIC Vac Network	\$34,194	Sep 2020- Jun 2021
Epitope mapping of schistosome tegument and gut proteins in humans	Egesa Moses Role: (Post-Doctoral fellowship)	MRC/UVRI and LSHTM Uganda Research Unit Department of Biology, University of York	MRC/UVRI and LSHTM Uganda Research Unit Post-Doctoral fellowship	\$46,693.30	Sept 2020- 2021

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Career Development Fellowship in poverty-related diseases and child and adolescent health Characterization of protein and glycan epitopes recognized following controlled human infection with <i>Schistosoma mansoni</i> in an endemic population	Egesa Moses (Fellow)	University of York, Wellcome Sanger Institute, and Leiden University Medical Center	EDCTP	\$182,378	2020-2023(3 years)
Uncovering <i>in vivo</i> anti-schistosome immune responses in endemic populations	Moses Egesa Role: Co-investigator (Post-doctoral Research Associate), PI: Dr James Hewitson	MRC/UVRI and LSHTM Uganda Research Unit Department of Biology, University of York	GCRF	\$30,564	2019
Clinical and immunological impact of <i>Schistosoma mansoni</i> infection and treatment on the course of hepatitis B virus (HBV) mono-infection and HIV/HBV coinfection among urban Ugandan	Egesa Moses Role: Co-investigator (Post-doctoral Research Associate), PI: Prof. Ponsiano Ocama	MRC/UVRI and LSHTM Uganda Research Unit Department of Medicine, Makerere University College of Health Sciences	National Institutes of Health	\$750,000	May 2020-Apr 2025
Hidden pathology of bone marrow remodelling in schistosomiasis	Egesa Moses Role: Co-investigator (Post-doctoral Research Associate), PI: Dr James Hewitson	MRC/UVRI and LSHTM Uganda Research Unit Department of Biology, University of York	Global Challenge Research Fund (GCRF)	\$38,547	Mar-Jul 2020
SARSCov2-3-20-002 Impact of co-infections and host genetics on susceptibility to SARS-CoV-2 infection and COVID-19 disease severity in well-studied cohorts in Uganda (CoHost)	Simon Kimuda Harriet Mpairwe , Joseph Mugisha, Alison Elliott , Pontiano Kaleebu	Uganda Virus Research Institute, MRC/UVRI and LSHTM Uganda Research Unit, Kings College London	African Academy of Sciences.	\$199,990	2020-2021

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
MUII staff					
A multi-centre Phase III Phase III double-blind, randomized, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG	Leander Grode (PI) MUII+ co-applicant Alison Elliott . UVRI local PI Anne Wajja (Honorary MUII Fellow)	Vakzine Projekt Management GmbH; numerous African partner institutions	EDCTP; India Serum Institute	€ 12,493,179	2018-2022
Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic parasitic infections	Alison Elliott (PI)	MRC/UVRI and LSHTM Uganda Research Unit	Medical Research Council, UK	£2,319,188	2018-2022
Crick African Network	Robert Wilkinson (PI); Stephen Cose (CoPI); Alison Elliott (CoPI); Pontiano Kaleebu (CoPI)	Crick Institute, UK MRC/UVRI; a consortium of African partners	MRC	£6,347,363	2017-2021
Human infection studies for Schistosoma mansoni vaccine testing in Uganda	Alison Elliott (PI)	MRC/UVRI and LSHTM Uganda Research Unit	Wellcome Trust	\$39,009	2019
Post-mortem studies on TB immunology	Stephen Cose	MRC/UVRI and LSHTM Uganda Research Unit	National Institute of Health	\$750,000	2019-2022
Human infection studies for Schistosoma mansoni vaccine testing in Uganda.	Alison Elliott (PI) & Steve Cose (Co-PI)	MRC/UVRI and LSHTM Uganda Research Unit, Leiden University Medical Centre; Texas Tech University Health Sciences Centre	Wellcome Trust	\$6,298,813	2020-2025
A Public engagement strategy to interrupt SARS-CoV-2 transmission in markets located in Kampala City, Uganda	Pamela Wairagala	The AAS in partnership with Wellcome and the United Kingdoms' Department for International Development (DFID)	MUII Plus	\$30,170	2020

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Subunit Vaccine for COVID-19. Development of a Subunit Vaccine for COVID-19 for Uganda.	Bernard Bagaya(PI)	Makerere University	Government of Uganda	\$462,901	2020
Establishment of Biobank of well annotated COVID-19 samples to support current and future research projects	Bernard Bagaya(Co-PI)	Makerere University	Government of Uganda	\$326,753	2020
Development of an Antigen Detection Agglutination based assay for diagnosis of COVID-19	Bernard Bagaya(Co-PI)	Makerere University	Government of Uganda	\$46,290	2020
Support to Makerere University to establish capacity for development of Molecular and Antibody-based Diagnostic kits for COVID-19 and other diseases	Bernard Bagaya(PI)	Makerere University	Government of Uganda	\$517,360	2020
Clinical Trial to test the efficacy of Convalescent Plasma in improving outcomes of severe COVID-19 in Uganda	Bernard Bagaya(PI)	Makerere University	MaKRIF	\$122,533	2020
Development of a Lateral Flow Immunofluorescence Cassette assay for detection of SARS CoV-2 in Oro/ Nasopharyngeal samples	Bernard Bagaya(PI)	Makerere University	TWED Property Development Ltd	\$47,107	2020
MUII centre members					
TrypanoGEN+: the genetic determinants of two neglected tropical diseases	Enock Matovu (PI); Alison Elliott (co-I)	Makerere University; UVRI; a consortium of African and UK partners.	H3Africa	~\$2,700,000 USD	2018-2021
Design and implement models and algorithms that predict possibility of HIV infection among young Ugandans and link them to care for prevention	Daudi Jjingo	Makerere University, Research and Innovation fund	Data Driven HIV Prevention Among Young Adults in Uganda	\$62,916	2019 - 2020

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
MUII alumni					
Target Malaria	Austin Burt (Global PI) Jonathan Kayondo (Collaborator/ UVRI PI)	Imperial College of Science, Technology and Medicine; UVRI; a consortium of global partners	Bill and Melinda Gates Foundation	\$1,880,323 (UVRI budget)	2016-2020
H3ABioNet: informatics solutions for H3Africa	Nicola Mulder (Consortium PI) Jonathan Kayondo (UVRI-Node PI)	University of Cape Town; UVRI; a consortium of African partners	NIH	\$378,000 (UVRI Budget)	2017-2021
Eastern Africa Network for Bioinformatics Training (EANBIT) Grant number	Dan Masiga (PI) Jonathan Kayondo; John Kitayimbwa (collaborators)	<i>icipe</i> ; Makerere University, UVRI, Uganda ; a consortium of East African partners	NIH Fogarty	\$1,180,000	2017-2021
Establishing Anopheles Mosquito Observatory in Uganda	Jonathan Kayondo	UVRI	Bill and Melinda Gates Foundation (BMGF) through Pan African Mosquito Control Association (PAMCA)	\$100,000	March 1st 2019 to Feb 29 2020
Immunological Selection of Recombinants following HIV-1 Superinfection (ISoReS).	Deogratius Ssemwanga (PI)	MRC/UVRI Unit	EDCTP	€ 150,000	2016-2019
Tracing mothers on option B+ and ascertainment of outcomes of their babies.	Agnes Kiragga (PI)	Infectious Diseases Institute;	EDCTP	€ 150,000	2016-2019
Tracing HIV positive women in urban Uganda and comparison of outcomes with retained women	Kara-Wools-Kaloustian (IU – PI) Agnes Kiragga (Uganda-PI)	University of Indiana, USA; Infectious Diseases Institute	NIH	\$235,000	2016-2017
Understanding asthma phenotypes: going beyond the atopic/non-atopic paradigm – Asthma Phenotypes	Neil Pearce – Study Principal Investigator Harriet Mpairwe – Project leader for the Uganda site	LSHTM; MRC/UVRI; 4 other study sites across the world.	European Research Council, Horizon 2020	€229,258 (for the Uganda site)	2016-2020

Grant title	Names of grant-holders (include role in project)	Key collaborating Institutions	Awarding Body	Amount	Grant period
Improving early detection and intervention for young infants at high-risk of neurodevelopmental delay and disability in Uganda	Maggie Nampijja (PI) Cally Tann and others (Co-PI)	MRC/UVRI Uganda; LSHTM; Kiwoko Hospital, Uganda; and others	Saving Brains/ Grand Challenges Canada	250,000 Canadian Dollars	2017-2019
Reproductive Health Empowerment through Telehealth (REHEAT)	Agnes Kiragga	Infectious Diseases Institute	PEER (Partnerships for Enhanced Engagement in Research; USAID)	\$199,150	2018-2020
PhD fellowship at the University of Georgia	Ronald Galiwango (former MUII strategic intern)	University of Georgia	NIH Fogarty International Center	Tuition and fees, health insurance, institutional materials and travel. The program also provides a stipend of \$38,849 annually i.e. ~\$160,000	2016-2020
Research: DAAD In Country/In Region Scholarship: Kenya	Criscent Birungi (Fellow)		DAAD	\$462	2020-2021

Appendix 2. Publications by MUII Fellows, Alumni and Staff

Publications by MUII Fellows, Honorary Fellows, Alumni and Staff 2020

1. Acur, A., Arias, R. S., Odongo, S., Tuhaise, S., Ssekandi, J., Adriko, J., **Muhanguzi, D.**, Buah, S., Kiggundu, A. (2020). Genetic diversity of aflatoxin-producing *Aspergillus flavus* isolated from selected groundnut growing agro-ecological zones of Uganda. *BMC Microbiology*, 20(1), 252. doi:10.1186/s12866-020-01924-
2. Akello M, Coutinho S, N-Mboowa MG, Bukirwa VD, Natukunda A, Lubyayi L, Nabakooza G, Cose S, **Elliott AM**. 2020. Continuous research monitoring improves the quality of research conduct and compliance among research trainees: internal evaluation of a monitoring programme. *AAS Open Research*, [version 1; peer review: awaiting peer review]. *AAS Open Res* 2020, 3:57 (<https://doi.org/10.12688/aasopenres.13117.1>)
3. Akurut, H., **Sanya, R. E., Lubyayi, L., Nampijja, M., Kizza, M., Kaweesa, J., Kizindo, R., Sewankambo, M., Nsubuga, D., Tukahebwa, E., Kabatereine, N. B., Elliott, A. M., Webb, E. L., & LaVILSWA trial team** (2020). Anthelmintic treatment receipt and its predictors in Lake Victoria fishing communities, Uganda: Intervention coverage results from the LaVILSWA cluster randomised trial. *PLoS neglected tropical diseases*, 14(10), e0008718. <https://doi.org/10.1371/journal.pntd.0008718>
4. Amany, S. B., B. Nyiro, F. Waswa, B. Obura, R. Nakaziba, E. Nabulime, A. F. Katabazi, **R. Nabatanzi**, A. Bayiyana, G. Mboowa, **A. Kayongo**, M. Wayengera, and O. J. Sande. 2020. Variations in Trim5α and Cyclophilin A genes among HIV-1 elite controllers and non controllers in Uganda: a laboratory-based cross-sectional study. *Retrovirology* 17 (1):19-19. doi:10.1186/s12977-020-00527-z
5. **Andia Biraro, I., E. Driciru, R. Namaganda, F. Luboga, C. Kato Drago, A. Wajja, B. Okech, M. Mboowa, R. Muganyizi, M. Kizza, S. Cose, V. Bukirwa, D. Nakanjako, and A. Elliott.** 2020. Analysis of the MUII-plus mentorship programme: reflections of Fellows? experiences and lessons for other programmes [version 1; peer review: awaiting peer review]. *AAS Open Research* 3 (37). doi:10.12688/aasopenres.13091.1
6. Ayitewala, A., F. Kyeyune, P. Ainembabazi, E. Nabulime, **C. D. Kato**, and I. Nankya. 2020. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. *AIDS research and therapy* 17 (1):2-2. doi:10.1186/s12981-020-0258-7
7. **Bayigga, L., Nabatanzi, R., Ssekagiri, A., Kateete, D. P., Sekikubo, M., Anderson, D. J., . . . Nakanjako, D.** (2020). Diverse vaginal microbiome was associated with pro-inflammatory vaginal milieu among pregnant women in Uganda. *Human Microbiome Journal*, 18, 100076. doi:<https://doi.org/10.1016/j.humic.2020.100076>
8. **Bbosa, N., D. Ssemwanga, A. Ssekagiri, X. Xi, Y. Mayanja, U. Bahemuka, J. Seeley, D. Pillay, L. Abeler-Dörner, T. Golubchik, C. Fraser, P. Kaleebu, and O. Ratmann.** 2020. Phylogenetic and Demographic Characterization of Directed HIV-1 Transmission Using Deep Sequences from High-Risk and General Population Cohorts/Groups in Uganda. *Viruses* 12 (3):331. doi:10.3390/v12030331
9. Bergey, C. M., M. Lukindu, R. M. Wiltshire, M. C. Fontaine, **J. K. Kayondo**, and N. J. Besansky. 2019. Assessing connectivity despite high diversity in island populations of a malaria mosquito. *Evolutionary applications* 13 (2):417-431. doi:10.1111/eva.12878
10. Berardi, A., Cassetti, T., Creti, R., Vocale, C., Ambretti, S., Sarti, M., Facchinetti, F., **Cose, S.**, Prepare Network, Heath, P., & Le Doare, K. (2020). The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against group B streptococcus. *Italian journal of pediatrics*, 46(1), 160. <https://doi.org/10.1186/s13052-020-00923-3>
11. **Cresswell, F., J. Kasibante, E. Martyn, L. Tugume, G. Stead, K. Ssembambulidde, M. Rutakingirwa, E. Kagimu, L. Nsangi, C. Namuju, J. Ndyetukira, C. Ahimbisibwe, F. Kugonza, A. Sadiq, A. Namudde, J. Dobbin, D. Srishyla, C. Quinn, M. Kabahubya, C. Muzoora, S. Watiti, D. Meya, and A. Elliott.** 2020. A Journey of Hope: giving research participants a voice to share their experiences and improve community engagement around advanced HIV disease in Uganda [version 1; peer review: 1 approved, 1 approved with reservations]. *AAS Open Research* 3 (33). doi:10.12688/aasopenres.13104.1
12. **Cresswell FV**, Ellis J, Kagimu E, Bangdiwala AS, Okirwoth M, Mugumya G, Rutakingirwa M, Kasibante J, Quinn CM, Ssembambulidde K, Rhein J, Nuwagira E, Tugume L, Martyn E, Skipper CP, Muzoora C, Grint D, Meya DB, Bahr NC, **Elliott AM**, Boulware DR. Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. *Open Forum Infect Dis*. 2020 Mar 24;7(4):ofaa100. doi: 10.1093/ofid/ofaa100. eCollection 2020 Apr
13. Cresswell FV, Tugume L, Bahr NC, Kwizera R, Bangdiwala AS, Musubire AK, Rutakingirwa M, Kagimu E, Nuwagira E, Mpoza E, Rhein J, Williams DA, Muzoora C, Grint D, Elliott AM, Meya DB, Boulware DR. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. *The Lancet Infectious Diseases*, 2020: p. S1473-3099(19)30550-X.
14. **Cresswell, F. V., Davis, A. G., Sharma, K., Basu Roy, R., Ganiem, A. R., Kagimu, E., Solomons, R., Wilkinson, R. J., Bahr, N. C., Thuong, N., & Tuberculous Meningitis International Research Consortium** (2020). Recent Developments in Tuberculous Meningitis Pathogenesis and Diagnostics. *Wellcome open research*, 4, 164. <https://doi.org/10.12688/wellcomeopenres.15506.2>
15. Donovan, J., **Cresswell, F. V., Thuong, N. T. T., Boulware, D. R., Thwaites, G. E., Bahr, N. C., & Consortium, T. M. I. R.** (2020). Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward. *Clinical Infectious Diseases*, 71(8), 2002-2005. doi:10.1093/cid/ciaa473

16. Eilu, E., Aliero, A. A., Odoki, M., Tibyangye, J., Akinola, S. A., Ntulume, I., Okweny, D., Okech, M. A., & **Kato, C. D.** (2020). Prevalence of cervical intraepithelial neoplasia and its associated factors among women attending healthcare services in Eastern Uganda. *Journal of Cancer Research and Experimental Oncology*, 12(1), 1-12.
17. Gahongayire, S., Almustapha Aliero, A., **Drago Kato, C.**, & Namatovu, A. (2020). Prevalence and Detection of *qac* Genes from Disinfectant-Resistant *Staphylococcus aureus* Isolated from Salon Tools in Ishaka Town, Bushenyi District of Uganda. *The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale*, 2020, 1470915. <https://doi.org/10.1155/2020/1470915>
18. Grant, H. E., E. B. Hodcroft, D. Ssemwanga, **J. M. Kitayimbwa**, G. Yebra, L. R. Esquivel Gomez, D. Frampton, A. Gall, P. Kellam, T. de Oliveira, N. Bbosa, R. N. Nsubuga, F. Kibengo, T. H. Kwan, S. Lycett, R. Kao, D. L. Robertson, O. Ratmann, C. Fraser, D. Pillay, P. Kaleebu, and A. J. Leigh Brown. 2020. Pervasive and non-random recombination in near full-length HIV genomes from Uganda. *Virus evolution* 6 (1):veaa004-veaa004. doi:10.1093/ve/veaa004
19. Hannaford, P. C., A. J. Thornton, P. Murchie, K. L. Whitaker, R. Adam, and **A. M. Elliott**. 2020. Patterns of symptoms possibly indicative of cancer and associated help-seeking behaviour in a large sample of United Kingdom residents-The USEFUL study. *PLOS ONE* 15 (1):e0228033-e0228033. doi:10.1371/journal.pone.0228033
20. Hitchcock, E. C., C. Study, and **A. M. Elliott**. 2020. Shortened consent forms for genome-wide sequencing: Parent and provider perspectives. *Molecular genetics & genomic medicine* 8 (7):e1254-e1254. doi:10.1002/mgg3.1254
21. **Iramiot, J. S.**, H. Kajumbula, J. Bazira, E. P. de Villiers, and **B. B. Asimwe**. 2020. Whole genome sequences of multi-drug resistant *Escherichia coli* isolated in a Pastoralist Community of Western Uganda: Phylogenomic changes, virulence and resistant genes. *PLOS ONE* 15 (5):e0231852-e0231852. doi:10.1371/journal.pone.0231852
22. **Iramiot JS**, Kajumbula H, Bazira J, Kansime C, **Asimwe BB**. Antimicrobial resistance at the human-animal interface in the Pastoralist Communities of Kasese District, South Western Uganda. *Sci Rep*. 2020 Sep 7;10(1):14737. doi: 10.1038/s41598-020-70517-w. PMID: 32895433; PMCID: PMC7477235.
23. Kabagenyi J, Natukunda A, Nassuuna J, Sanya RE, Nampijja M, Well EL, **Elliott AM**, **Nkurunungi G**. Urban-rural differences in immune responses to mycobacterial and tetanus vaccine antigens in a tropical setting: a role for helminths? *Parasitology International*, 2020 Oct;78:102132. doi: 10.1016/j.parint.2020.102132. Epub 2020 May 5.
24. Kagimu, E., E. Martyn, J. Gakuru, J. Kasibante, M. Rutakingirwa, R. Kwizera, K. Ssebambulidde, D. Williams, J. Ellis, F. Cresswell, and D. Meya. 2020. COVID-19 and the HIV care continuum in Uganda: minimising collateral damage [version 1; peer review: 1 approved with reservations]. *AAS Open Research* 3 (28). doi:10.12688/aasopenres.13099.1
25. Katamba, A., M. D. Ogwang, D. S. Zamar, H. Muyinda, A. Oneka, **S. Atim**, K. Jongbloed, S. S. Malamba, T. Odongping, A. J. Friedman, P. M. Spittal, N. K. Sewankambo, and M. T. Schechter. 2020. Congo Lyc (Healing the Elephant): HIV incidence in post-conflict Northern Uganda. *EclinicalMedicine* 23:100408-100408. doi:10.1016/j.eclinm.2020.100408
26. **Katongole, P.**, F. Nalubega, N. C. Florence, **B. Asimwe**, and **I. Andia**. 2020. Biofilm formation, antimicrobial susceptibility and virulence genes of Uropathogenic *Escherichia coli* isolated from clinical isolates in Uganda. *BMC Infectious Diseases* 20 (1):453. doi:10.1186/s12879-020-05186-1
27. **Kimuda, S. G.**, I. Andia-Biraro, I. Sebina, M. Egesa, A. Nalwoga, S. G. Smith, B. S. Bagaya, J. Levin, A. M. Elliott, J. G. Raynes, and **S. Cose**. 2020. Mycobacterium tuberculosis infection is associated with increased B cell responses to unrelated pathogens. *Scientific reports* 10 (1):14324-14324. doi:10.1038/s41598-020-71044-4
28. Kinyanjui S, Fonn S, Kyobutungi C, Vincente-Crespo M, Bonfoh B, N'dungu T, Djimde A, Sewankambo N, Gaye O, Chirwa T, Musenge E, **Elliott A**, Nakanjako D, Chibanda, D, Awandare G. Enhancing science preparedness for health emergencies in Africa through research capacity building: The African Research Coalition for Health (ARCH) example. *BMJ Glob Health* 2020 Jul;5(7):e003072. (editorial)
29. Kirenga, B., Muttamba, W., Kayongo, A., Nsereko, C., Siddharthan, T., Lusiba, J., Bagaya, B.S., Kateete, D.P., . . . Bazeyo, W. (2020). Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. *BMJ Open Respiratory Research*, 7(1), e000646. doi:10.1136/bmjresp-2020-000646
30. Kyohere, M., Davies, H. G., Musoke, P., **Nakimuli, A.**, **Tusubira, V.**, Tasimwa, H. B., Nsimire, J. S., Heath, P., **Cose, S.**, Baker, C., Le Doare, K., & Sekikubo, M. (2020). Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS. *Gates open research*, 4, 155. <https://doi.org/10.12688/gatesopenres.13183.2>
31. Letang, E., Ellis, J., Naidoo, K., Casas, E. C., Sánchez, P., Hassan-Moosa, R., **Cresswell, F.**, Miró, J. M., & García-Basteiro, A. L. (2020). Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out. *Archivos de bronconeumologia*, 56(7), 446–454. <https://doi.org/10.1016/j.arbres.2019.11.015>
32. Lubyayi, L., P. A. Mawa, G. Nabakooza, M. Nakibuule, J. V. Tushabe, J. Serubanja, D. Aibo, H. Akurut, J. Tumusiime, M. Hasso-Agopsowicz, P. Kaleebu, J. Levin, H. M. Dockrell, S. Smith, E. L. Webb, **A. M. Elliott**, and **S. Cose**. 2020. Maternal Latent Mycobacterium tuberculosis Does Not Affect the Infant Immune Response Following BCG at Birth: An Observational Longitudinal Study in Uganda. *Frontiers in immunology* 11:929-929. doi:10.3389/fimmu.2020.00929
33. Masyuko SJ, Page ST, Kinuthia J, Osoti AO, Polyak SJ, Otieno FC, Kibachio JM, Mogaka JN, Temu TM, Zifodya JS, Otedo A, **Nakanjako D**, Hughes JP, Farquhar C. Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults: A cross-sectional study. *Medicine (Baltimore)*. 2020 Jul 2;99(27):e20845. doi: 10.1097/MD.00000000000020845. PMID: 32629671; PMCID: PMC7337552.
34. **Martin N Mayanja**, Frank N Mwiine, Alain Kohl, Emma C Thomson, Julius J Lutwama. An update on the mosquito species composition and diversity in western and North Western Uganda. *J Entomol Zool Stud* 2020;8(2):1074-1086.
35. Mayito, J., **I. Andia Biraro**, S. T. Reece, A. R. Martineau, and **D. P. Kateete**. 2020. Detection of Mycobacterium tuberculosis DNA in CD34+ peripheral blood mononuclear cells of Ugandan adults with latent infection: a cross-sectional and nested prospective study [version 1; peer review: 2 approved]. *AAS Open Research* 3 (34). doi:10.12688/aasopenres.13108.1

36. **Mpairwe H, Nkurunungi G**, Tumwesige P, Akurut H, Namutebi M, Nambuya I, Nnaluwoza M, Apule B, Onen C, Katongole T, Niwagaba E, Mukasa M, Webb E, **Elliott A**, Pearce N. Risk factors for rhinitis, allergic conjunctivitis and eczema among schoolchildren in Uganda. *Clin Exp Allergy*, in press. <https://medrxiv.org/cgi/content/short/2020.06.03.20121251v1>
37. Mubuuke, A. G., S. N. Mbalinda, I. G. Munabi, **D. Kateete**, R. B. Opoka, and S. Kiguli. 2020. Knowledge, attitudes and practices of faculty on mentorship: an exploratory interpretivist study at a sub-Saharan African medical school. *BMC medical education* 20 (1):192-192. doi:10.1186/s12909-020-02101-9
38. **Muhanguzi, D.**, Byaruhanga, J., Amanyire, W., Ndekezi, C., Ochwo, S., Nkamwesiga, J., Mwiine, F. N., Tweyongyere, R., Fourie, J., Madder, M., Schetters, T., Horak, I., Juleff, N., & Jongejan, F. (2020). Invasive cattle ticks in East Africa: morphological and molecular confirmation of the presence of *Rhipicephalus microplus* in south-eastern Uganda. *Parasites & vectors*, 13(1), 165. <https://doi.org/10.1186/s13071-020-04043-z>
39. Mutua, A. M., **Nampijja, M.**, **Elliott, A. M.**, Pettifor, J. M., Williams, T. N., Abubakar, A., Webb, E. L., & Atkinson, S. H. (2020). Vitamin D Status Is Not Associated with Cognitive or Motor Function in Pre-School Ugandan Children. *Nutrients*, 12(6), 1662. <https://doi.org/10.3390/nu12061662>
40. Mutua, A.M., Mogire, R.M., **Elliott, A.**, Williams, T., Webb, E., Abubakar, A., & Atkinson, S. (2020). Effects of vitamin D deficiency on neurobehavioural outcomes in children: a systematic review. *Wellcome open research*, 5, 28 doi.org/10.12688/wellcomeopenres.15730.2
41. Muriuki JM, Mentzer AJ, Webb EL, Morovat A, Kimita W, Ndungu FM, Macharia AW, Crane RJ, Berkley JA, Lule SA, Cutland C, Sirima SB, Diarra A, Tiono AB, Bejon P, Madhi SA, Hill AVS, Prentice AM, Suchdev PS, **Elliott AM**, Williams TN, and Atkinson SH. Estimating the burden of iron deficiency among African children. *BMC Medicine*, 2020. 18(1): p. 31-31. doi:10.1186/s12916-020-1502-7
42. Nabbaale, J., E. Okello, D. Kibirige, I. Ssekitoleko, J. Isanga, P. Karungi, E. Sebatta, Z. W. Zhu, **A. Nakimuli**, J. Omagino, and J. Kayima. 2020. Burden, predictors and short-term outcomes of peripartum cardiomyopathy in a black African cohort. *PLOS ONE* 15 (10):e0240837. doi:10.1371/journal.pone.0240837
43. Naggirinya, A. B., A. Mujugira, D. B. Meya, **I. A. Biraro**, E. Mupere, W. Worodria, and Y. C. Manabe. 2020. Functional adrenal insufficiency among tuberculosis-human immunodeficiency virus co-infected patients: a cross-sectional study in Uganda. *BMC research notes* 13 (1):224-224. doi:10.1186/s13104-020-05064-8
44. **Nakanjako, D.**, F. Zalwango, P. Wairagala, F. Luboga, I. Andia Biraro, V. Bukirwa, M. Mboowa, **S. Cose**, J. Seeley, and **A. Elliott**. 2020. Career development for infection and immunity research in Uganda: a decade of experience from the Makerere University ? Uganda Virus Research Institute research and training programme [version 2; peer review: 2 approved]. *AAS Open Research* 3 (26). doi:10.12688/aasopenres.13066.2
45. **Nalwoga, A.**, Webb, E. L., Muserere, C., Chihota, B., Miley, W., Labo, N., **Elliott, A.**, **Cose, S.**, Whitby, D., & Newton, R. (2020). Variation in KSHV prevalence between geographically proximate locations in Uganda. *Infectious agents and cancer*, 15, 49. <https://doi.org/10.1186/s13027-020-00313-8>
46. **Nalwoga, A.**, Nakibuule, M., Marshall, V., Miley, W., Labo, N., **Cose, S.**, Whitby, D., & Newton, R. (2020). Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 71(4), 1055–1062. <https://doi.org/10.1093/cid/ciz916>
47. Martyn, E. M., Bangdiwala, A. S., Kagimu, E., Rutakingirwa, M. K., Kasibante, J., Okirwoth, M., . . . **Cresswell, F. V.** (2020). Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus–Associated Tuberculous Meningitis. *Clinical Infectious Diseases*. doi:10.1093/cid/ciaa1444
48. Matovu, E., Katiti, D., Kitibwa, A., Kazibwe, A., **Kato, C. D.**, Biéler, S., & Ndung'u, J. M. (2020). Optimisation of template preparation and laboratory evaluation of the Loopamp™ Trypanosoma brucei kit for detection of parasite DNA in blood. *Experimental parasitology*, 211, 107844. Advance online publication. <https://doi.org/10.1016/j.exppara.2020.107844>
49. Namakula, R., de Bree, L., A Tvedt, T. H., Netea, M. G., **Cose, S.**, & Hanevik, K. (2020). Monocytes from neonates and adults have a similar capacity to adapt their cytokine production after previous exposure to BCG and β -glucan. *PLoS one*, 15(2), e0229287. <https://doi.org/10.1371>
50. **Namale, G.**, Kamacooko, O., Makhoba, A., Mugabi, T., Ndagire, M., Ssanyu, P., . . . Newton, R. (2020). Predictors of 30-day and 90-day mortality among hemorrhagic and ischemic stroke patients in urban Uganda: a prospective hospital-based cohort study. *BMC Cardiovascular Disorders*, 20(1), 442. doi:10.1186/s12872-020-01724-6
51. **Nampijja, M.**, **Lubyayi, L.**, Tumusiime J, Nabulime J, Kizindo R, Kabuubi P, Sanya RE, Kabagenyi J, Akurut H, Muhangi L, Webb EL, Alcock K, **Elliott, A.M.**, for the LaVIISWA Trial Team. Effect of intensive versus standard anthelmintic treatment on growth and cognition among children living in a high *Schistosoma mansoni* transmission setting: a study nested within a cluster-randomised trial [version 1; peer review: awaiting peer review]. *Wellcome Open Res* 2020, 5:258 (<https://doi.org/10.12688/wellcomeopenres.16092.1>)
52. Namutebi M., Nnaluwoza M, Tumwesige P, Mukasa M, Apule B, Onen C, Katongole T, Tumusiime J., Akurut H, **Elliott A**, Mpairwe H.,(2020)., Lessons learnt in recruiting schoolchildren into a large asthma case-control study in urban Uganda [version 1; peer review: awaiting peer review]. *Wellcome Open Res* 2020, 5:251 (<https://doi.org/10.12688/wellcomeopenres.16371.1>)
53. **Nanvubya, A.**, Wanyenze, R. K., Nakaweese, T., Mpendo, J., Kawoozo, B., Matovu, F., . . . Van Geertruyden, J. P. (2020). Correlates of knowledge of family planning among people living in fishing communities of Lake Victoria, Uganda. *BMC Public Health*, 20(1), 1642. doi:10.1186/s12889-020-09762-7

54. **Nanvubya A**, Wanyenze RK, Kamacooko O, Nakaweesa T, Mpendo J, Kawoozo B, Matovu F, Nabukalu S, Omoding G, Kaweesi J, Ndugga J, **Bagaya B**, Chinyenze K, Price M, Van Geertruyden JP. Barriers and Facilitators of Family Planning Use in Fishing Communities of Lake Victoria in Uganda. *J Prim Care Community Health*. 2020 Jan-Dec;11:2150132720943775. doi: 10.1177/2150132720943775. PMID: 32698653; PMCID: PMC7378720.
55. Natukunda A, **Nkurunungi G**, **Zirimenya L**, **Nassuuna J**, Oduru G, Amongin R, Kabuubi PN, Mutebe A, Onen C, Amongi S, Nakazibwe E, Akello F, Kiwanuka S, Kiwudhu F, Sewankambo M, Nsubuga D, Kizindo R, Staedke SG, **Cose S**, Webb EL, **Elliott AM** for the POPVAC trial team. The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACCine responses' (POPVAC) programme. *BMJ Open*, in press.
56. Nayebare, P., Asua, V., Conrad, M. D., Kajubi, R., Kakuru, A., Nankabirwa, J. I., Muhanguzi, D., Dorsey, G., Kamya, M. R., Nsoya, S., & Rosenthal, P. J. (2020). Associations between Malaria-Preventive Regimens and Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Ugandan Pregnant Women. *Antimicrobial agents and chemotherapy*, 64(12), e01047-20. <https://doi.org/10.1128/AAC.01047-20>
57. Ndagire, B., Mwesigwa, C. L., Ntuulo, J. M., Mayanja-Kizza, H., **Nakanjako, D.**, & Rwenyonyi, C. M. (2020). Dental Caries Pattern and Treatment Needs among Ugandan Adolescent Students: A Cross-Sectional Study. *International Journal of Dentistry*, 2020, 8135865. doi:10.1155/2020/8135865
58. Nekaka, R., J. Nteziyaremye, P. Oboth, **J. S. Iramiot**, and J. Wandabwa. 2020. Malaria preventive practices and delivery outcomes: A cross-sectional study of parturient women in a tertiary hospital in Eastern Uganda. *PLOS ONE* 15 (8):e0237407-e0237407. doi:10.1371/journal.pone.0237407
59. **Nkurunungi G**, **Mpairwe H**, Versteeg SA, van Diepen A, **Nassuuna J**, Kabagenyi J, Nambuya I, Sanya RE, Nampijja M, Serna S, Reichardt N, Hokke CH, Webb EL, ban Ree R, Yazdanbakhsh M, **Elliott AM**. Cross-reactive carbohydrate determinant-specific IgE obscures true atopy and exhibits α -1,3-fucose epitope-specific inverse associations with asthma. *Allergy*. 2020 Jun 22. doi: 10.1111/all.14469. Online ahead of print.
60. **Nkurunungi G**, **Zirimenya L**, **Nassuuna J**, Natukunda A, Kabuubi P, Niwagaba E, Oduru G, Kabami G, Amongin R, Mutebe A, Namutebi M, Zziwa C, Amongi S, Ninsiima C, Onen C, Akello F, Sewankambo M, Kiwanuka S, Kizindo R, Kaweesa J, **Cose S**, Webb EL, **Elliott AM** for the POPVAC trial team. The effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACCine responses' (POPVAC) programme. *BMJ Open*, in press.
61. Nkurunungi G, Zirimenya L, Natukunda A, Nassuuna J, Oduru G, Nansiima C, Zziwa C, Akello F, Kizindo R, Akello M, Kaleebu P, Wajja A, Luzze H, Cose S, Webb EL, **Elliott AM** for the POPVAC trial team. Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics. *BMJ Open*, in press.
62. Nchu, F., Nyangiwe, N., **Muhanguzi, D.**, Nzalawahe, J., Nagagi, Y. P., Msalya, G., Joseph, N. A., Kimaro, E. G., Mollel, M., Temba, V., & Harouna, D. V. (2020). Development of a practical framework for sustainable surveillance and control of ticks and tick-borne diseases in Africa. *Veterinary world*, 13(9), 1910–1921. <https://doi.org/10.14202/vetworld.2020.1910-1921>
63. Nsamba, J., S. A. Lule, B. Namara, C. Zziwa, H. Akurut, L. Lubyayi, F. Akello, J. Tumusiime, **A. M. Elliott**, and E. L. Webb. 2020. Effect of birth weight, exclusive breastfeeding and growth in infancy on fat mass and fat free mass indices in early adolescence: an analysis of the Entebbe Mother and Baby Study (EMaBs) cohort. *AAS Open Research* 2:11-11. doi:10.12688/aasopenres.12947.2
64. Odoki, M., A. A. Aliero, J. Tibyangye, J. N. Maniga, E. Eilu, I. Ntulume, E. Wampande, **C. D. Kato**, E. Agwu, and J. Bazira. 2020. Fluoroquinolone resistant bacterial isolates from the urinary tract among patients attending hospitals in Bushenyi District, Uganda. *The Pan African medical journal* 36:60-60. doi:10.11604/pamj.2020.36.60.18832
65. Prentice, S., E. L. Webb, H. M. Dockrell, **P. Kaleebu**, **A. M. Elliott**, and **S. Cose**. 2020. Correction to: Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial. *Trials* 21 (1):707-707. doi:10.1186/s13063-020-04594-7
66. Prentice S, Webb EL, Akello FA, Kiwudhu DF, Akurut H, **Elliott AM**, Dockrell HM, **Cose S**. BCG-induced non-specific protection against heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. *Lancet Infectious Diseases* in press.
67. Quinn, C. M., Poplin, V., Kasibante, J., Yuquimpo, K., Gakuru, J., **Cresswell, F. V.**, & Bahr, N. C. (2020). Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease. *Life (Basel, Switzerland)*, 10(11), 262. <https://doi.org/10.3390/life10110262>
68. Rohlwink, U., Chow, F., Wasserman, S., Dian, S., Lai, R., Chaidir, L., **Cresswell FV.**, . . . null, n. (2020). Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies [version 2; peer review: 2 approved]. *Wellcome Open Research*, 4(204). doi:10.12688/wellcomeopenres.15497.2
69. Rutakingirwa, M. K., **Cresswell, F. V.**, **Kwizera, R.**, Ssebambulidde, K., Kagimu, E., Nuwagira, E., . . . Rhein, J. (2020). Tuberculosis in HIV-Associated Cryptococcal Meningitis is Associated with an Increased Risk of Death. *Journal of Clinical Medicine*, 9(3), 781.
70. **Sanya, R. E.**, E. L. Webb, C. Zziwa, R. Kizindo, M. Sewankambo, J. Tumusiime, E. Nakazibwe, G. Oduru, E. Niwagaba, P. K. Nakawungu, J. Kabagenyi, J. Nassuuna, B. Walusimbi, **I. Andia-Biraro**, and **A. M. Elliott**. 2020. The Effect of Helminth Infections and Their Treatment on Metabolic Outcomes: Results of a Cluster-Randomized Trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 71 (3):601-613. doi:10.1093/cid/ciz859

71. **Sanya RE, Andia Biraro I, Nampijja M, Zziwa C, Nanyunja C, Nsubuga D, Kiwanuka S, Tumusiime J, Nassuuna J, Walusimbi B, Cose S, Ocama P, Grencis R, Elliott AM, Webb EL.** Contrasting impact of rural, versus urban, living on glucose metabolism and blood pressure in Uganda [version 1; peer review: awaiting peer review]. *Wellcome Open Res* 2020, 5:39 (<https://doi.org/10.12688/wellcomeopenres.15616.1>)
72. **Ssemwanga, D., Bbosa, N., Nsubuga, R. N., Ssekagiri, A., Kapaata, A., Nannyonjo, M., Nassolo, F., Karabarinde, A., Mugisha, J., Seeley, J., Yebra, G., Leigh Brown, A., & Kaleebu, P.** (2020). The Molecular Epidemiology and Transmission Dynamics of HIV Type 1 in a General Population Cohort in Uganda. *Viruses*, 12(11), 1283. <https://doi.org/10.3390/v12111283>
73. **Ssengooba, W.,** Iragena, J. D., Nakiyingi, L., Mujumbi, S., Wobudeya, E., Mboizi, R., Boulware, D., Meya, D. B., Choo, L., Crook, A. M., Lebeau, K., Joloba, M., Demers, A. M., **Cresswell, F. V.,** & Gibb, D. M. (2020). Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial. *Journal of clinical microbiology*, 58(9), e00410-20. <https://doi.org/10.1128/JCM.00410-20>
74. Ssekatawa, K., Byarugaba, D. K., **Kato, C. D.,** Ejobi, F., Tweyongyere, R., Lubwama, M., . . . Wampande, E. M. (2020). Nanotechnological solutions for controlling transmission and emergence of antimicrobial-resistant bacteria, future prospects, and challenges: a systematic review. *Journal of Nanoparticle Research*, 22(5), 117. doi:10.1007/s11051-020-04817-7
75. Ssekatawa, K., **Kato, C.,** Wampande, E., Lubwama, M., & Kirabira, J. (2020). Recent advances in the development of COVID-19 vaccines using lessons learned from nanosized and nano enabled adjuvant vaccine delivery system research for coronaviruses: A systematic review. DOI: [10.13140/RG.2.2.12509.64487](https://doi.org/10.13140/RG.2.2.12509.64487)
76. Ssetaala, A., Nabawanuka, J., Matovu, G., **Nakiragga, N.,** Namugga, J., Nalubega, P., Kaluuma, H. L., Chinyenze, K., Perehudoff, K., Michielsen, K., **Bagaya, B.,** Price, M., Kiwanuka, N., & Degomme, O. (2020). Components of antenatal care received by women in fishing communities on Lake Victoria, Uganda; a cross sectional survey. *BMC health services research*, 20(1), 901. <https://doi.org/10.1186/s12913-020-05739-9>
77. Ssetaala, A., Nabawanuka, J., Matovu, G., **Nakiragga, N.,** Namugga, J., Nalubega, P., Lutalo Kaluuma, H., Perehudoff, K., Michielsen, K., **Bagaya, B.,** Kiwanuka, N., & Degomme, O. (2020). Antenatal Care Practices Among Hard-to-Reach Fishing Communities on Lake Victoria: A Community-Based Cross-Sectional Survey. *Journal of Primary Care & Community Health*. <https://doi.org/10.1177/2150132720923101>
78. Stadelman, A. M., Ellis, J., Samuels, T., Mutengesa, E., Dobbin, J., Ssebambulidde, K., Rutakingirwa, M. K., Tugume, L., Boulware, D. R., Grint, D., & **Cresswell, F. V.** (2020). Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis. *Open forum infectious diseases*, 7(8), ofaa257. <https://doi.org/10.1093/ofid/ofaa257>
79. **Tukwasibwe, S., A. Nakimuli,** J. Traherne, O. Chazara, J. Jayaraman, J. Trowsdale, A. Moffett, P. Jagannathan, P. J. Rosenthal, **S. Cose,** and F. Colucci.(2020). Variations in killer-cell immunoglobulin-like receptor and human leukocyte antigen genes and immunity to malaria. *Cellular & Molecular Immunology* 17 (8):799-806. doi:10.1038/s41423-020-0482-z
80. **Tushabe, J. V., Lubyayi, L.,** Sserubanja, J., Kabuubi, P., Abayo, E., Kiwanuka, S., Nassuuna, J., Kaweesa, J., Corstjens, P., van Dam, G., **Sanya, R. E.,** Ssenyonga, W., Tukahebwa, E. M., Kabatereine, N. B., **Elliott, A. M.,** Webb, E. L., & LaVIISWA trial team (2020). Does Intensive Treatment Select for Praziquantel Resistance in High-Transmission Settings? Parasitological Trends and Treatment Efficacy Within a Cluster-Randomized Trial. *Open forum infectious diseases*, 7(4), ofaa091. <https://doi.org/10.1093/ofid/ofaa091>
81. Tucker, E. W., Marais, S., Seddon, J. A., van Crevel, R., Ganiem, A. R., Ruslami, R., Zhang, W., Sun, F., Zhou, X., Solomons, R. S., **Cresswell, F. V.,** Wilmshurst, J., & Rohlwink, U. (2020). International Survey Reveals Opportunities to Improve Tuberculous Meningitis Management and the Need for Standardized Guidelines. *Open forum infectious diseases*, 7(11), ofaa445. <https://doi.org/10.1093/ofid/ofaa445>
82. **Twesigomwe, D.,** Wright, G., Drögemöller, B. I., da Rocha, J., Lombard, Z., & Hazelhurst, S. (2020). A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on *CYP2D6* genotyping. *NPJ genomic medicine*, 5, 30. <https://doi.org/10.1038/s41525-020-0135-2>
83. Zirimenya L, Nkurunungi G, Nassuuna J, Natukunda A, Mutebe A, Oduru G, Kabami G, Akurut H, Onen C, Namutebi M, Serubanja J, Nakazibwe E, Akello F, Tumusiime J, Sewankambo M, Kiwanuka S, Kiwudhu F, Kizindo R, Kizza M, Wajja A, Cose S, Muwanga M, Webb EL, **Elliott AM** for the POPVAC trial team. The impact of Bacillus Calmette-Guérin Revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACCine responses' (POPVAC) programme. *BMJ Open*, in press.

2019

1. Abaasa A, Asiki G, Obuku Ekii A, Wanyenze J, Pala P, J van Dam G, Corstjens PLAM, Hughes P, Ding S, Pantaleo G, **Kaleebu P, Elliott AM,** Kamali A. [Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and Schistosoma mansoni co-infected patients: a randomised controlled trial](https://doi.org/10.12688/wellcomeopenres.14683.2). Version 2. *Wellcome Open Res*. 2019 Apr 3 [revised 2019 Jan 1] ;3:81. doi: 10.12688/wellcomeopenres.14683.2
2. Aker EAO, Nabaggala MS, Kaimal A, Nalwanga D, Castelnovo B, Musubire A, **Kiragga A,** Lamorde M, Ratanshi RP. [An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir](https://doi.org/10.1186/s12879-019-3907-5). *Infect Dis*. 2019 Mar 25;19(1):280. doi: 10.1186/s12879-019-3907-5.

3. Anguzu G, Flynn A, Musaazi J, Kasirye R, Atuhaire LK, **Kiragga AN**, Kabagenyi A, Mujugira A. Relationship between socioeconomic status and risk of sexually transmitted infections in Uganda: Multilevel analysis of a nationally representative survey. Int J STD AIDS. 2019 Mar;30(3):284-291. doi: 10.1177/0956462418804115
4. **Anywaine Z**, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, Anumendem D, Luhn K, Robinson C, Douoguih M, Watson-Jones DJ. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. Infect Dis. 2019 Jun 5;220(1):46-56. doi: 10.1093/infdis/jiz070.
5. Aruhomukama D, Najjuka CF, Kajumbula H, Okee M, Mboowa G, Sserwadda I, Mayanja R, Joloba ML, **Kateete DP**. bla_{VIM}- and bla_{OXA}-mediated carbapenem resistance among Acinetobacter baumannii and Pseudomonas aeruginosa isolates from the Mulago hospital intensive care unit in Kampala, Uganda. BMC Infect Dis. 2019 Oct 16;19(1):853. doi: 10.1186/s12879-019-4510-5.
6. Atherton RR, **Cresswell FV**, Ellis J, Kitaka SB, Boulware DR. Xpert MTB/RIF Ultra for Tuberculosis Testing in Children: A Mini-Review and Commentary. Front Pediatr. 2019 Feb 28;7:34. doi: 10.3389/fped.2019.00034. eCollection 2019. Review.
7. Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, **Ssemwanga D**, Fehr J, Castelnuevo B, Sekaggya-Wiltshire C, von Braun A. Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943.
8. Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, **Ssemwanga D**, Fehr J, Castelnuevo B, Sekaggya-Wiltshire C, von Braun A. Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943.
9. **Bayigga L**, **Kateete DP**, Anderson DJ, Sekikubo M, **Nakanjako D**. Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention. Am J Obstet Gynecol. 2019 Feb;220(2):155-166. doi: 10.1016/j.ajog.2018.10.014
10. Bayiyana A, Okurut S, **Nabatanzi R**, Zziwa G, Boulware DR, Lutwama F, Meya D. Longitudinal Changes in Cd4⁺, Cd8⁺, T Cell Phenotype and Activation Marker Expression Following Antiretroviral Therapy Initiation among Patients with Cryptococcal Meningitis. J Fungi (Basel). 2019 Jul 17;5(3). pii: E63. doi: 10.3390/jof5030063.
11. **Bbosa N**, Kaleebu P, **Ssemwanga D**. HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019 May;14(3):153-160. doi: 10.1097/COH.0000000000000534.
12. **Bbosa N**, **Ssemwanga D**, **Nsubuga RN**, Salazar-Gonzalez JF, Salazar MG, Nanyonjo M, Kuteesa M, Seeley J, Kiwanuka N, **Bagaya BS**, Yebra G, Leigh-Brown A, Kaleebu P. Phylogeography of HIV-1 suggests that Ugandan fishing communities are a sink for, not a source of, virus from general populations. Sci Rep. 2019 Jan 31;9(1):1051. doi: 10.1038/s41598-018-37458-x.
13. Bomboka JB, **N-Mboowa MG**, Nakilembe J. Post - effects of obstetric fistula in Uganda; a case study of fistula survivors in KITOBU mission hospital (MASAKA), Uganda. BMC Public Health. 2019 Jun 6;19(1):696. doi: 10.1186/s12889-019-7023-7
14. **Cresswell FV**, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R. Intensified antibiotic treatment of tuberculosis meningitis. Expert Rev Clin Pharmacol. 2019 Mar;12(3):267-288. doi: 10.1080/17512433.2019.1552831. Epub 2019 Feb 12. Review. PMID:30474434
15. **Cresswell FV**, Tugume L, Bahr NC, Kwizera R, Bangdiwala AS, Musubire AK, Rutakingirwa M, Kagimu E, Nuwagira E, Mpoza E, Rhein J, Williams DA, Muzoora C, Grint D, **Elliott AM**, Meya DB, Boulware DR; ASTRO-CM team. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infect Dis. 2020 Jan 7. pii: S1473-3099(19)30550-X. doi: 10.1016/S1473-3099(19)30550-X
16. Kwizera R, **Cresswell FV**, Mugumya G, Okirwoth M, Kagimu E, Bangdiwala AS, Williams DA, Rhein J, Boulware DR, Meya DB. Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients. Version 2. Wellcome Open Res. 2019 Sep 30 [revised 2019 Jan 1];4:123. doi: 10.12688/wellcomeopenres.15389.2. eCollection 2019
17. **Cummings MJ**, Tokarz R, **Bakamutumaho B**, Kayiwa J, Byaruhanga T, Owor N, Namagambo B, Wolf A, Mathema B, Lutwama JJ, Schluger NW, Lipkin WI, O'Donnell MR. Precision Surveillance for Viral Respiratory Pathogens: Virome Capture Sequencing for the Detection and Genomic Characterization of Severe Acute Respiratory Infection in Uganda. Clin Infect Dis. 2019 Mar 19;68(7):1118-1125. doi: 10.1093/cid/ciy656.
18. De Francesco D, Winston A, Underwood J, **Cresswell FV**, Anderson J, Post FA, Williams I, Mallon PW, Sachikonye M, Babalis D, Vera JH, Bagkeris E, Milinkovic A, Sabin CA. Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. Int J STD AIDS. 2019 Apr;30(5):440-446. doi: 10.1177/0956462418817612. Epub 2019 Jan 10.

19. Ellis J, Bangdiwala AS, **Cresswell FV**, Rhein J, Nuwagira E, Ssebambulidde K, Tugume L, Rajasingham R, Bridge SC, Muzoora C, Meya DB, Boulware DR. The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015-2017. Open Forum Infect Dis. 2019 Sep 29;6(10):ofz419. doi: 10.1093/ofid/ofz419. eCollection 2019 Oct. Erratum in: Open Forum Infect Dis. 2019 Dec 03;6(12):ofz506.
20. Ellis J, Eneh PC, Ssebambulidde K, Rutakingirwa MK, Lamorde M, Rhein J, **Cresswell FV**, Boulware DR, Nicol MR. Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. Version 2. Wellcome Open Res. 2019 Jan 15 [revised 2019 Jan 1];3:111. doi: 10.12688/wellcomeopenres.14726.2.
21. **Fatumo S**, Carstensen T, Nashiru O, Gurdasani D, Sandhu M, **Kaleebu P**. Complimentary Methods for Multivariate Genome-Wide Association Study Identify New Susceptibility Genes for Blood Cell Traits Front Genet. 2019 Apr 26;10:334. doi: 10.3389/fgene.2019.00334. eCollection 2019.
22. Galiwango RM, **Bagaya B**, Mpendo J, Joag V, Okech B, **Nanvubya A**, Ssetaala A, Muwanga M, Kaul R. Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men. Trials. 2019 Jul 19;20(1):443. doi: 10.1186/s13063-019-3545-7.
23. Galiwango RM, Yegorov S, Joag V, Prodger J, Shahabi K, Huibner S, Muyanja E, Kabuubi BR, Namuniina A, Nalutaaya A, Ssemaganda A, Lutwama F, Kitandwe PK, **Nanvubya A**, Mpendo J, **Bagaya B**, Kiwanuka N, Kaul R. Characterization of CD4+ T cell subsets and HIV susceptibility in the inner and outer foreskin of Ugandan men Am J Reprod Immunol. 2019 Jul;82(1):e13143. doi: 10.1111/aji.13143. Epub 2019 May 24
24. **Gertrude N**, Kawuma R, Nalukenge W, Kamacooko O, Yperzeele L, Cras P, Ddumba E, Newton R, Seeley J. Caring for a stroke patient: The burden and experiences of primary caregivers in Uganda - A qualitative study Nurs Open. 2019 Aug 4;6(4):1551-1558. doi: 10.1002/nop2.356. eCollection 2019 Oct.
25. Gurdasani D, Carstensen T, **Fatumo S**, Chen G, Franklin CS, Prado-Martinez J, Bouman H, Abascal F, Haber M, Tachmazidou I, Mathieson I, Ekoru K, DeGorter MK, **Nsubuga RN**, Finan C, Wheeler E, Chen L, Cooper DN, Schiffels S, Chen Y, Ritchie GRS, Pollard MO, Fortune MD, Mentzer AJ, Garrison E, Bergström A, Hatzikotoulas K, Adeyemo A, Doumatey A, Elding H, Wain LV, Ehret G, Auer PL, Kooperberg CL, Reiner AP, Franceschini N, Maher D, Montgomery SB, Kadie C, Widmer C, Xue Y, Seeley J, Asiki G, Kamali A, Young EH, Pomilla C, Soranzo N, Zeggini E, Pirie F, Morris AP, Heckerman D, Tyler-Smith C, Motala AA, Rotimi C, Kaleebu P, Barroso I, Sandhu MS. Uganda Genome Resource Enables Insights into Population History and Genomic Discovery in Africa. Cell. 2019 Oct 31;179(4):984-1002.e36. doi: 10.1016/j.cell.2019.10.004.
26. Habarugira G, Nkuranga C, **Asiimwe B**, Turikumwenayo JB, Ojok L. First confirmed case of bovine besnoitiosis in Rwanda. Vet Parasitol Reg Stud Reports. 2019 Aug;17:100294. doi: 10.1016/j.vprsr.2019.100294. Epub 2019 Apr 24.
27. Idro R, Anguzu R, Ogwang R, Akun P, Abbo C, Mwaka AD, Opar B, Nakamya P, Taylor M, **Elliott A**, Vincent A, Newton C, Marsh K. Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial. BMC Neurol. 2019 Mar 6;19(1):35. doi: 10.1186/s12883-019-1256-z
28. Iramiot JS, Rwego IB, Kansiime C, **Asiimwe BB**. Epidemiology and antibiotic susceptibility of Vibrio cholerae associated with the 2017 outbreak in Kasese district, Uganda BMC Public Health. 2019 Oct 29;19(1):1405. doi: 10.1186/s12889-019-7798-6.
29. Kalanzi D, Mayanja-Kizza H, **Nakanjako D**, Mwesigwa CL, Ssenyonga R, Amaechi BT. Prevalence and factors associated with dental caries in patients attending an HIV care clinic in Uganda: a cross sectional study BMC Oral Health. 2019 Jul 19;19(1):159. doi: 10.1186/s12903-019-0847-9.
30. Kalungi A, Womersley JS, Kinyanda E, Joloba ML, Ssembajjwe W, **Nsubuga RN**, Levin J, **Kaleebu P**, Kidd M, Seedat S, Hemmings SMJ. Internalizing Mental Disorders and Accelerated Cellular Aging Among Perinatally HIV-Infected Youth in Uganda. Front Genet. 2019 Aug 2;10:705. doi: 10.3389/fgene.2019.00705. eCollection 2019.
31. **Kateete DP**, **Asiimwe BB**, Mayanja R, Mujuni B, Bwanga F, Najjuka CF, Källander K, Rutebemberwa E. Nasopharyngeal carriage, spa types and antibiotic susceptibility profiles of Staphylococcus aureus from healthy children less than 5 years in Eastern Uganda BMC Infect Dis. 2019 Dec 2;19(1):1023. doi: 10.1186/s12879-019-4652-5.
32. **Kateete DP**, Bwanga F, Seni J, Mayanja R, Kigozi E, Mujuni B, Ashaba FK, Baluku H, Najjuka CF, Källander K, Rutebemberwa E, **Asiimwe BB**, Joloba ML. CA-MRSA and HA-MRSA coexist in community and hospital settings in Uganda. Antimicrob Resist Infect Control. 2019 Jun 3;8:94. doi: 10.1186/s13756-019-0551-1
33. **Kateete DP**, Edolu M, Kigozi E, Kisukye J, Baluku H, Mwiine FN, Najjuka CF. Species, antibiotic susceptibility profiles and van gene frequencies among enterococci isolated from patients at Mulago National Referral Hospital in Kampala, Uganda BMC Infect Dis. 2019 May 31;19(1):486. doi: 10.1186/s12879-019-4136-7.
34. Kavuma Mwanje A, Ejoku J, Ssemogerere L, Lubulwa C, Namata C, Kwizera A, Wabule A, Okello E, Kizito S, Lubikire A, Sendagire C, **Andia Biraro I**. Association between CD4 T cell counts and the immune status among adult critically ill HIV-negative patients in intensive care units in Uganda [version 1; peer review: 1 approved, 2 approved with reservations]. AAS Open Res 2019, 2:2 (<https://doi.org/10.12688/aasopenres.12925.1>)

35. Kibirige D, **Sanya RE**, Nantanda R, Worodria W, Kirenga B. Availability and affordability of medicines and diagnostic tests recommended for management of asthma and chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. *Allergy Asthma Clin Immunol*. 2019 Mar 7;15:14. doi: 10.1186/s13223-019-0329-2. eCollection 2019.
36. **Kiragga AN**, Mubiru F, Kambugu AD, Kamya MR, Castelnuovo B. A decade of antiretroviral therapy in Uganda: what are the emerging causes of death? *BMC Infect Dis*. 2019 Jan 21;19(1):77. doi: 10.1186/s12879-019-3724-x.
37. Kitonsa J, Mayanja Y, Aling E, Kiwanuka J, Namutundu J, **Anywaine Z**, Ggayi AB, Kibengo F, Kiwanuka N, Kaleebu P. Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda *PLoS One*. 2019 Jan 30;14(1):e0210287. doi: 10.1371/journal.pone.0210287. eCollection 2019
38. Koopman JP, Egesa M, Wajja A, Adriko M, Nassuuna J, **Nkurunungi G**, Driciru E, van Willigen G, Cose S, Yazdanbakhsh M, **Kaleebu P**, Kabatereine N, Tukahebwa E, Roestenberg M, **Elliott AM**. Risk assessment for the implementation of controlled human *Schistosoma mansoni* infection trials in Uganda. *AAS Open Res*. 2019 Aug 13;2:17. doi: 10.12688/aasopenres.12972.2.
39. Kumuthini J, Zass L, Panji S, Salifu SP, **Kayondo JK**, Nembaware V, Mbiyavanga M, Olabode A, Kishk A, Wells G, Mulder NJ; The H3ABioNet helpdesk: an online bioinformatics resource, enhancing Africa's capacity for genomics research as members of the Sustainability and Outreach Work Package of the H3ABioNet Consortium. *BMC Bioinformatics*. 2019 Dec 30;20(1):741. doi: 10.1186/s12859-019-3322-3.
40. Kuteesa MO, Weiss HA, Abaasa A, Nash S, **Nsubuga RN**, Newton R, Seeley J, Kamali A. Feasibility of conducting HIV combination prevention interventions in fishing communities in Uganda: A pilot cluster randomised trial *PLoS One*. 2019 Mar 27;14(3):e0210719. doi: 10.1371/journal.pone.0210719. eCollection 2019.
41. Kyosiimire-Lugemwa J, **Anywaine Z**, Abaasa A, Levin J, Gombe B, Musinguzi K, Kaleebu P, Grosskurth H, Munderi P, Pala P. Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy. *J Infect Dis*. 2019 Oct 23. pii: jiz494. doi: 10.1093/infdis/jiz494.
42. Laker EAO, Nabaggala MS, Kaimal A, Nalwanga D, Castelnuovo B, Musubire A, **Kiragga A**, Lamorde M, Ratanshi RP. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir *BMC Infect Dis*. 2019 Mar 25;19(1):280. doi: 10.1186/s12879-019-3907-5
43. **Lule SA**, Mentzer AJ, Namara B, Muwenzi AG, Nassanga B, Kizito D, Akurut H, Lubyayi L, Tumusiime J, Zziwa C, Akello F, Gurdasani D, Sandhu M, Smeeth L, **Elliott AM**, Webb EL. A genome-wide association and replication study of blood pressure in Ugandan early adolescents. *Mol Genet Genomic Med*. 2019 Oct;7(10):e00950. doi: 10.1002/mgg3.950. Epub 2019 Aug 30.
44. **Lule SA**, Namara B, Akurut H, Lubyayi L, Nampijja M, Akello F, Tumusiime J, Aujo JC, Oduru G, Mentzer AJ, Smeeth L, Elliott AM, Webb EL. Blood pressure risk factors in early adolescents: results from a Ugandan birth cohort. *J Hum Hypertens*. 2019 Sep;33(9):679-692. doi: 10.1038/s41371-019-0178-y. Epub 2019 Feb 25.
45. **Lule SA**, Namara B, Akurut H, Muhangi L, Lubyayi L, Nampijja M, Akello F, Tumusiime J, Aujo JC, Oduru G, Smeeth L, **Elliott AM**, Webb EL. Are birthweight and postnatal weight gain in childhood associated with blood pressure in early adolescence? Results from a Ugandan birth cohort. *Int J Epidemiol*. 2019 Feb 1;48(1):148-156. doi: 10.1093/ije/dyy118
46. Lwanga I, Nabaggala MS, **Kiragga A**, Calcagno A, Guaraldi G, Lamorde M, Castelnuovo B. Implementing routine physical function screening among elderly HIV-positive patients in Uganda. *AIDS Care*. 2019 Dec 17:1-4. doi: 10.1080/09540121.2019.1703888
47. Mabonga E, Parkes-Ratanshi R, Riedel S, **Nabweyambo S**, Mbabazi O, Taylor C, Gaydos C, Manabe YC. Complete ciprofloxacin resistance in gonococcal isolates in an urban Ugandan clinic: findings from a cross-sectional study. *Int J STD AIDS*. 2019 Mar;30(3):256-263. doi: 10.1177/0956462418799017.
48. Masereka EM, Ngabirano TD, Osingada CP, Wiltshire CS, Castelnuovo B, **Kiragga AN**. Increasing retention of HIV positive pregnant and breastfeeding mothers on option-b plus by upgrading and providing full time HIV services at a lower health facility in rural Uganda *BMC Public Health*. 2019 Jul 15;19(1):950. doi: 10.1186/s12889-019-7280-5.
49. Mayito J, **Andia I**, Belay M, Jolliffe DA, **Kateete DP**, Reece ST, Martineau AR. Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection. *J Infect Dis*. 2019 Feb 15;219(5):685-694. doi: 10.1093/infdis/jiy579
50. Meya DB, **Kiragga AN**, Nalintya E, Morawski BM, Rajasingham R, Park BJ, Mubiru A, Kaplan JE, Manabe YC, Boulware DR. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/ μ L: A Stepped-Wedge, Cluster-Randomized Trial. *J Acquir Immune Defic Syndr*. 2019 Feb 1;80(2):182-189. doi: 10.1097/QAI.0000000000001894.

51. Meya, D. B., Okurut, S., Zziwa, G., **Cose, S.**, Boulware, D. R., & Janoff, E. N. (2019). HIV-Associated Cryptococcal Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function and Increased Cytokine Responses. *J Fungi (Basel)*, 5(2). doi:10.3390/jof5020042
52. Mosepele M, Kanyama C, Meya D, **Cresswell FV**, Chammard, T.B., Mwandumba, H.C., Meintjes, G., Mfinanga, G.S., Ndhlovu, C.E., & Jarvis, J.N. Introducing a new Africa meningitis network – a north-south collaboration. PO 8719. *BMJ Global Health*. 2019;4(3):A63. DOI:10.1136/bmjgh-2019-edc.165
53. **Mpairwe H**, Amoah AS. Parasites and allergy: Observations from Africa. *Parasite Immunol*. 2019 Jun;41(6):e12589. doi: 10.1111/pim.12589.
54. **Mpairwe H**, Namutebi M, **Nkurunungi G**, Tumwesige P, Nambuya I, Mukasa M, Onen C, Nnaluwooza M, Apule B, Katongole T, Oduru G, Kahwa J, Webb EL, **Lubyayi L**, Pearce N, Elliott AM. Risk factors for asthma among schoolchildren who participated in a case-control study in urban Uganda. *Elife*. 2019 Nov 15;8. pii: e49496. doi: 10.7554/eLife.49496
55. Mulder NJ, Adebisi E, Adebisi M, Adeyemi S, Ahmed A, Ahmed R, Akanle B, Alibi M, Armstrong DL, Aron S, Ashano E, Baichoo S, Benkahl A, Brown DK, Chimusa ER, Fadlilmola FM, Falola D, Fatumo S, Ghedira K, Ghouila A, Hazelhurst S, Isewon I, Jung S, Kassim SK, **Kayondo JK**, Mbiyavanga M, Meintjes A, Mohammed S, Mosaku A, Moussa A, Muhammd M, Mungloo-Dilmohamud Z, Nashiru O, Odia T, Okafor A, Oladipo O, Osamor V, Oyelade J, Sadki K, Salifu SP, Soyemi J, Panji S, Radouani F, Souiai O, Tastan Bishop Ö; Development of Bioinformatics Infrastructure for Genomics Research H3ABioNet Consortium, as members of the H3Africa Consortium. *Glob Heart*. 2017 Jun;12(2):91-98. doi: 10.1016/j.gheart.2017.01.005
56. Muriuki JM, Mentzer AJ, Band G, Gilchrist JJ, Carstensen T, Lule SA, Goheen MM, Joof F, Kimita W, Mogire R, Cutland CL, Diarra A, Rautanen A, Pomilla C, Gurdasani D, Rockett K, Mturi N, Ndungu FM, Scott JAG, Sirima SB, Morovat A, Prentice AM, Madhi SA, Webb EL, **Elliott AM**, Bejon P, Sandhu MS, Hill AVS, Kwiatkowski DP, Williams TN, Cerami C, Atkinson SH. The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. *Sci Adv*. 2019 Sep 4;5(9):eaaw0109. doi: 10.1126/sciadv.aaw0109. eCollection 2019 Sep
57. **Muriuki JM**, Mentzer AJ, Kimita W, Ndungu FM, Macharia AW, Webb EL, **Lule SA**, Morovat A, Hill AVS, Bejon P, **Elliott AM**, Williams TN, Atkinson SH. Iron Status and Associated Malaria Risk Among African Children. *Clin Infect Dis*. 2019 May 17;68(11):1807-1814. doi: 10.1093/cid/ciy791.
58. Muwanguzi PA, Nassuna LK, Voss JG, Kigozi J, Muganzi A, Ngabirano TD, **Sewankambo N**, **Nakanjako D**. Towards a definition of male partner involvement in the prevention of mother-to-child transmission of HIV in Uganda: a pragmatic grounded theory approach. *BMC Health Serv Res*. 2019 Aug 9;19(1):557. doi: 10.1186/s12913-019-4401-x.
59. **Nabatanzi R**, **Bayigga L**, **Cose S**, Rowland Jones S, Joloba M, Canderan G, **Nakanjako D**. Monocyte Dysfunction, Activation, and Inflammation After Long-Term Antiretroviral Therapy in an African Cohort. *J Infect Dis*. 2019 Sep 26;220(9):1414-1419. doi: 10.1093/infdis/jiz320.
60. **Nabatanzi R**, **Bayigga L**, **Cose S**, Rowland-Jones S, Canderan G, Joloba M, **Nakanjako D**. Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohort. *Clin Immunol*. 2019 Apr;201:55-60. doi: 10.1016/j.clim.2019.02.010. Epub 2019 Feb 26
61. **Nalwoga A**, Nakibuule M, Marshall V, Miley W, Labo N, Cose S, Whitby D, Newton R. Risk factors for Kaposi's sarcoma associated herpesvirus (KSHV) DNA in blood and in saliva in rural Uganda. *Clin Infect Dis*. 2019 Sep 26. pii: ciz916. doi: 10.1093/cid/ciz916
62. **Nalwoga A**, Webb EL, Chihota B, Miley W, Walusimbi B, Nassuuna J, Sanya RE, Nkurunungi G, Labo N, **Elliott AM**, **Cose S**, Whitby D, Newton R. Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands. *PLoS Negl Trop Dis*. 2019 Oct 16;13(10):e0007776. doi: 10.1371/journal.pntd.0007776. eCollection 2019 Oct.
63. Namuniina A, Lutwama F, Biribawa VM, Kizza D, Kabuubi BR, Kitandwe PK, Mpendo J, Nanvubya A, Ssempiira J, Nalutaaya A, Ssetaala A, Welsh S, Price MA, Kiwanuka N, **Bagaya BS**. Field Performance of PIMA Point-of-Care Machine for CD4 Enumeration Under a Mobile HIV Counseling and Testing Program in Remote Fishing Communities of Lake Victoria, Uganda. *AIDS Res Hum Retroviruses*. 2019 Apr;35(4):382-387. doi: 10.1089/AID.2018.0223. Epub 2019 Feb 14.
64. Nasuuna E, Kigozi J, Muwanguzi PA, Babirye J, Kiwala L, Muganzi A, Sewankambo N, **Nakanjako D**. Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study. *BMC health services research*. 2019 Dec 19(1), 150. doi:10.1186/s12913-019-3963-y
65. Ndekezi C, Nkamwesiga J, Ochwo S, Kimuda MP, Mwiine FN, **Tweyongyere R**, Amanyire W, **Muhanguzi D**. Identification of Ixodid Tick-Specific Aquaporin-1 Potential Anti-tick Vaccine Epitopes: An *in-silico* Analysis. *Front Bioeng Biotechnol* 2019 Sep 26;7:236. doi: 10.3389/fbioe.2019.00236
66. **Nkurunungi G**, Lubyayi L, Versteeg SA, Sanya RE, Nassuuna J, Kabagenyi J, Kabuubi PN, Tumusiime J, Zziwa C, Kizindo R, Niwagaba E, Nanyunja C, Nampijja M, Mpairwe H, Yazdanbakhsh M, van Ree R, Webb EL, Elliott AM. Do helminth infections underpin urban-rural differences in risk factors for allergy-related outcomes? *Clin Exp Allergy*. 2019 May;49(5):663-676. doi: 10.1111/cea.13335. Epub 2019 Jan 25.

67. **Nkurunungi G**, van Diepen A, Nassuuna J, Sanya RE, Nampijja M, Nambuya I, Kabagenyi J, Serna S, Reichardt NC, van Ree R, Webb EL, Elliott AM, Yazdanbakhsh M, Hokke CH. Microarray assessment of N-glycan-specific IgE and IgG profiles associated with Schistosoma mansoni infection in rural and urban Uganda. Sci Rep. 2019 Mar 5;9(1):3522. doi: 10.1038/s41598-019-40009-7.
68. Nsanya MK, Kavishe BB, Katende D, Mosha N, Hansen C, **Nsubuga RN**, Munderi P, Grosskurth H, Kapiga S. Prevalence of high blood pressure and associated factors among adolescents and young people in Tanzania and Uganda Clin Hypertens (Greenwich). 2019 Apr;21(4):470-478. doi: 10.1111/jch.13502. Epub 2019 Feb 27.
69. Nsubuga J, **Kato CD**, Nanteza A, Matovu E, Alibu VP. Plasma cytokine profiles associated with rhodesiense sleeping sickness and falciparum malaria co-infection in North Eastern Uganda. Allergy Asthma Clin Immunol. 2019 Oct 30;15:63. doi: 10.1186/s13223-019-0377-7.
70. Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, Blumberg L, Asogun D, Mukonka V, **Lule SA**, Bates M, Honeyborne I, Mfinanga S, Mwaba P, Dar O, Vairo F, Mukhtar M, Kock R, McHugh TD, Ippolito G, Zumla A. Monkeypox - Enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era Int J Infect Dis. 2019 Jan;78:78-84. doi: 10.1016/j.ijid.2018.11.008
71. Ramachandran PS, **Cresswell FV**, Meya DB, Langelier C, Crawford ED, DeRisi JL, Boulware DR, Wilson MR. Detection of Cryptococcus DNA by Metagenomic Next-generation Sequencing in Symptomatic Cryptococcal Antigenemia. Clin Infect Dis. 2019 May 17;68(11):1978-1979. doi: 10.1093/cid/ciy1024.
72. **Sanya RE, Nkurunungi G**, Hoek Spaans R, Nampijja M, O'Hara G, Kizindo R, Oduru G, Kabuubi Nakawungu P, Niwagaba E, Abayo E, Kabagenyi J, Zziwa C, Tumusiime J, Nakazibwe E, Kaweesa J, Muwonge Kakooza F, Akello M, Lubyayi L, Verweij J, Nash S, van Ree R, **Mpairwe H**, Tukahebwa E, Webb EL, **Elliott AM**; LaVIISWA Trial Team. The Impact of Intensive Versus Standard Anthelmintic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial. Clinical Infectious Diseases, 68(10), 1665-1674. doi:10.1093/cid/ciy761
73. **Sanya RE**, Webb EL, Zziwa C, Kizindo R, Sewankambo M, Tumusiime J, Nakazibwe E, Oduru G, Niwagaba E, Kabuubi Nakawungu P, Kabagenyi J, **Nassuuna J, Walusimbi B, Biraro IA, Elliott AM**; LaVIISWA trial team. The effect of helminth infections and their treatment on metabolic outcomes: results of a cluster-randomised trial. Clin Infect Dis. 2019 Aug 30. pii: ciz859. doi: 10.1093/cid/ciz859. [Epub ahead of print].
74. Siya A, Bazeyo W, **Tuhebwe D**, Tumwine G, Ezama A, Manirakiza L, Kugonza DR, Rwego IB. Lowland grazing and Marburg virus disease (MVD) outbreak in Kween district, Eastern Uganda. BMC Public Health. 2019 Jan 31;19(1):136. doi: 10.1186/s12889-019-6477-y.
75. Ssebambulidde K, Bangdiwala AS, Kwizera R, Kandole TK, Tugume L, Kiggundu R, Mpoza E, Nuwagira E, Williams DA, Lofgren SM, Abassi M, Musubire AK, **Cresswell FV**, Rhein J, Muzoora C, Hullsiek KH, Boulware DR, Meya DB; Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis. Adjunctive Sertraline for Treatment of HIV-associated Cryptococcal Meningitis Team .
76. Stockdale L, **Nalwoga A**, Nash S, Elias S, Asiki G, Kusemererwa S, Gilchrist JJ, Newton R, MacLennan CA. Cross-sectional study of IgG antibody levels to invasive nontyphoidal Salmonella LPS O-antigen with age in Uganda. Gates Open Res. 2019 Jun 26;3:1501. doi: 10.12688/gatesopenres.13034.1. eCollection 2019.
77. Stockdale L, Nash S, **Nalwoga A**, Gibson L, Painter H, Raynes J, Asiki G, Newton R, Fletcher H. HIV, HCMV and mycobacterial antibody levels: a cross-sectional study in a rural Ugandan cohort. Trop Med Int Health. 2019 Feb;24(2):247-257. doi: 10.1111/tmi.13188
78. **Tweyongyere R, Nassanga BR**, Muhwezi A, Odongo M, **Lule SA, Nsubuga RN**, Webb EL, Cose SC, **Elliott AM** Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles catch-up immunisation in pre-school children: A randomised trial. PLoS Negl Trop Dis. 2019 Feb 14;13(2):e0007157. doi: 10.1371/journal.pntd.0007157. eCollection 2019 Feb.
79. Umotoy J, **Bagaya BS**, Joyce C, Schiffner T, Menis S, Saye-Francisco KL, Biddle T, Mohan S, Vollbrecht T, Kalyuzhnyi O, Madzorera S, Kitchin D, Lambson B, Nonyane M, Kilembe W; IAVI Protocol C Investigators; IAVI African HIV Research Network, Poignard P, Schief WR, Burton DR, Murrell B, Moore PL, Briney B, Sok D, Landais E. Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan. munity. 2019 Jul 16;51(1):141-154.e6. doi: 10.1016/j.immuni.2019.06.004.
80. Vousden N, Lawley E, Seed PT, Gidiri MF, Charantimath U, Makonyola G, Brown A, Yadeta L, Best R, Chinkoyo S, Vwalika B, **Nakimuli A**, Ditai J, Greene G, Chappell LC, Sandall J, Shennan AH; Exploring the effect of implementation and context on a stepped-wedge randomised controlled trial of a vital sign triage device in routine maternity care in low-resource settings. CRADLE Trial Collaborative Group. Implement Sci. 2019 Apr 18;14(1):38. doi: 10.1186/s13012-019-0885-3.
81. **Wajja A**, Namutebi M, Apule B, Oduru G, Kiwanuka S, **Akello M**, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, **Cose S**, Levin J, Kaleebu P, Tukahebwa E, McShane H, **Elliott AM**. Lessons from the first clinical

trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1.

82. **Wampande EM**, Naniima P, Mupere E, **Kateete DP**, Malone LL, Stein CM, Mayanja-Kizza H, Gagneux S, Boom WH, Joloba ML. Genetic variability and consequence of Mycobacterium tuberculosis lineage 3 in Kampala-Uganda. PLoS One. 2019 Sep 9;14(9):e0221644. doi: 10.1371/journal.pone.0221644. eCollection 2019.
83. Wokorach G, Edema H, **Muhanguzi D**, Echodu R. Prevalence of sweetpotato viruses in Acholi sub-region, northern Uganda. Curr Plant Biol. 2019 Jan;17:42-47. doi: 10.1016/j.cpb.2019.03.001.
84. Yegorov S, Joag V, Galiwango RM, Good SV, Mpendo J, Tannich E, Boggild AK, Kiwanuka N, **Bagaya BS**, Kaul R. Schistosoma mansoni treatment reduces HIV entry into cervical CD4+ T cells and induces IFN- γ pathways. Nat Commun. 2019 May 24;10(1):2296. doi: 10.1038/s41467-019-09900-9.
85. Ingabire PM, Semitala F, Kanya MR, and **Nakanjako D**. Delayed Antiretroviral Therapy (ART) Initiation among Hospitalized Adults in a Resource-Limited Settings: A Challenge to the Global Target of ART for 90% of HIV-Infected Individuals. AIDS research and treatment, 2019. **2019**: p. 1832152-1832152.
86. **Kateete DP**, Kamulegeya R, Kigozi E, Katabazi FA, Lukoye D, Sebiri SI, Abdi H, Arube P, Kasule GW, Musisi K, Dlamini MG, Khumalo D, and Joloba ML. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016). BMC pulmonary medicine, 2019. **19**(1): p. 124-124.
87. Omooja J, Nannyonjo M, Sanyu G, Nabirye SE, Nassolo F, Lunkuse S, Kapaata A, Segujja F, **Kateete DP**, Ssebagala E, **Bbosa N**, Aling E, **Nsubuga RN**, Kaleebu P, and **Ssemwanga D**. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. The Journal of antimicrobial chemotherapy, 2019. **74**(10): p. 3021-3029.
88. Nguna J, Dione M, Apamaku M, Majalija S, Mugizi DR, Odoch T, **Kato CD**, Tumwine G, Kabaasa JD, Curtis K, Graham M, Ejobi F, and Graham T. Seroprevalence of brucellosis and risk factors associated with its seropositivity in cattle, goats and humans in Iganga District, Uganda. The Pan African medical journal, 2019. **33**: p. 99-99.
89. Baluku JB, Nassozi S, Gyagenda B, Namanda M, **Andia-Biraro I**, Worodria W, and Byakika-Kibwika P. Prevalence of Malaria and TB Coinfection at a National Tuberculosis Treatment Centre in Uganda. Journal of tropical medicine, 2019. **2019**: p. 3741294-3741294.
90. Kalyesubula R, Mutyaaba I, Rabin T, **Andia-Biraro I**, Alupo P, Kimuli I, Nabirye S, Kagimu M, Mayanja-Kizza H, Rastegar A, and Kanya MR. Trends of admissions and case fatality rates among medical in-patients at a tertiary hospital in Uganda; A four-year retrospective study. PloS one, 2019. **14**(5): p. e0216060-e0216060.
91. Muttamba W, **Kyobe S**, Komuhangi A, Lakony J, Buregyeya E, Mabumba E, and Basaza RK. Delays in diagnosis and treatment of pulmonary tuberculosis in patients seeking care at a regional referral hospital, Uganda: a cross sectional study. BMC research notes, 2019. **12**(1): p. 589-589.
92. Shoemaker TR, Nyakarahuka L, Balinandi S, Ojwang J, Tumusiime A, Mulei S, Kyondo J, Lubwama B, Sekamatte M, Namutebi A, Tusiime P, Monje F, **Mayanja M**, Ssendagire S, Dahlke M, Kyazze S, Wetaka M, Makumbi I, Borchert J, Zufan S, Patel K, Whitmer S, Brown S, Davis WG, Klena JD, Nichol ST, Rollin PE, and Lutwama J. First Laboratory-Confirmed Outbreak of Human and Animal Rift Valley Fever Virus in Uganda in 48 Years. The American journal of tropical medicine and hygiene, 2019. **100**(3): p. 659-671.

2018

1. Ali, S., Byanyima R. K., **Ononge S.**, Ichtho, J., Nyamwiza J., Loro E. L. E., . . . Karamagi, C. (2018). Measurement error of mean sac diameter and crown-rump length among pregnant women at Mulago hospital, Uganda. *BMC Pregnancy Childbirth*, 18(1), 129. doi: 10.1186/s12884-018-1769-2
2. Anguzu G, Flynn A, Musaazi J, Kasirye R, Atuhaire LK, **Kiragga AN**, Kabagenyi A, Mujugira A. (2018 Nov 11). Relationship between socioeconomic status and risk of sexually transmitted infections in Uganda: Multilevel analysis of a nationally representative survey. *Int J STD AIDS*.:956462418804115. PMID: 30417749
3. Atherton RR, **Cresswell FV**, Ellis J, Skipper C, Tadeo KK, Mugumya G, Wadda V, Meya DB, Boulware DR. (2018 Oct). Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: A useful adjunctive diagnostic tool in HIV-associated tuberculosis. *Int J Infect Dis*.:75:92-94. PMID: 30031800
4. Atherton RR, Ellis J, **Cresswell FV**, Rhein J, Boulware DR. (2018 Oct 12) Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort. Version 2. *Wellcome Open Res*.:3:80. PMID: 30345376
5. Averbach S, **Kakaire O**, McDiehl R, Dehlendorf C, Lester F, Steinauer J. (2018 Nov 6). The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial. *Contraception*. pii: S0010-7824(18)30480-3. doi:10.1016/j.contraception.2018.10.008. [Epub ahead of print] PMID:30408456
6. Bahr NC, Boulware DR, **Cresswell FV**. (2018 Mar). Xpert Ultra's place in the diagnosis of tuberculous meningitis. *Lancet Infect Dis*.18(3):249-250. PMID: 29485087
7. Bahr NC, Nuwagira E, Evans EE, **Cresswell FV**, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala AS, Meya DB, Denkinger CM, Muzoora C, Boulware DR; ASTRO-CM Trial Team. Diagnostic accuracy of Xpert MTB/RIF Ultra for

- tuberculous meningitis in HIV-infected adults: a prospective cohort study. *Lancet Infect Dis*. 2018 Jan;18(1):68-75. PMID: 28919338
8. **Bayigga L, Kateete DP, Anderson DJ, Sekikubo M, Nakanjako D**. 2018 Oct 12. Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention. *Am J Obstet Gynecol*. PMID: 30321529
 9. Bayigga L, Kateete DP, Anderson DJ, **Sekikubo M**, Nakanjako D. Diversity of
 10. Beatrice Mwilike, Gorrette Nalwadda, **Mike Kagawa**, Khadija Malima, Lilian Mselle and Shigeko Horiuchi. Knowledge of danger signs during pregnancy and subsequent healthcare seeking actions among women in Urban Tanzania: a cross-sectional study. *BMC Pregnancy and Childbirth* (2018) 18:4 DOI 10.1186/s12884-017-1628-6 <https://www.ncbi.nlm.nih.gov/pubmed/29295710>
 11. Bisaso KR, Karungi SA, **Kiragga A**, Mukonzo JK, Castelnuevo B. A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients. *BMC Med Inform Decis Mak*. 2018 Sep 4;18(1):77. PMID: 30180893
 12. Blokhuis JH, Hilton HG, Guethlein LA, Norman PJ, Nemat-Gorgani N, **Nakimuli A**, Chazara O, Moffett A, Parham P. KIR2DS5 allotypes that recognize the C2 epitope of HLA-C are common among Africans and absent from Europeans. *Immun Inflamm Dis*. 2017 Dec;5(4):461-468. doi: 10.1002/iid3.178. Epub 2017 Jul 6.
 13. Buhikire K, Voss J, Kigozi J, Nyakato P, Ankunda N, Kalebbo B, Musiitwa M, Muganzi A, Sewankambo NK, **Nakanjako D**. Reaching the First 90 in Uganda: Predictors of Success in Contacting and Testing the Named Sexual Partners of HIV+ Index Clients in Kiboga District. *AIDS Behav*. 2018 Aug;22(8):2458-2467. PMID: 29754266
 14. Byakika-Kibwika P, Nyakato P, Lamorde M, **Kiragga AN**. Assessment of parasite clearance following treatment of severe malaria with intravenous artesunate in Ugandan children enrolled in a randomized controlled clinical trial. *Malar J*. 2018 Oct 30;17(1):400. PMID: 30376860
 15. Castelnuevo B, Mubiru F, **Kiragga AN**, Musomba R, Mbabazi O, Gonza P, Kambugu A, Ratanshi RP. Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda. *BMJ Open*. 2018 Feb 21;8(2):e015490. PMID: 29467129
 16. Castelnuevo B, Mubiru F, Nakalema S, Twimukye A, **Kiragga A**. Describing the retention in care of human immunodeficiency virus-positive young adults who transition from adolescent to adult care. *Int Health*. 2018 Jul 1;10(4):318-320. PMID: 29401288
 17. Cervical Cancer Screening in Kampala, Uganda. *J Glob Oncol*. 2018 Sep;(4):1-9.
 18. Chammartin F, Zürcher K, Keiser O, Weigel R, Chu K, **Kiragga AN**, Ardura-Garcia C, Anderegg N, Laurent C, Cornell M, Tweya H, Haas AD, Rice BD, Geng EH, Fox MP, Hargreaves JR, Egger M. Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis. *Clin Infect Dis*. 2018 Nov 13;67(11):1643-1652. PMID: 29889240
 19. Christine Atuhairwe, **Dinah Amongin**, Elly Agaba, Steven Mugarura, Ivan Mugisha Taremwa. The effect of knowledge on uptake of breast cancer prevention modalities among women in Kyadondo County, Uganda. *BMC public health* 2018. doi: 10.1186/s12889-018-5183-5
 20. Community-based HPV self-collection versus visual inspection with acetic acid in
 21. **Cresswell FV**, Bangdiwala AS, Bahr NC, Trautner E, Nuwagira E, Ellis J, Rajasingham R, Rhein J, Williams DA, Muzoora C, Elliott AM, Meya DB, Boulware DR. Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. *Wellcome Open Res*. 2018 May 29;3:64. PMID: 30027125
 22. **Cresswell FV**, Bangdiwala AS, Meya DB, Bahr NC, Vidal JE, Török ME, Thao LTP, Thwaites GE, Boulware DR. Absence of cerebrospinal fluid pleocytosis in tuberculous meningitis is a common occurrence in HIV co-infection and a predictor of poor outcomes. *Int J Infect Dis*. 2018 Mar;68:77-78. PMID: 29391245
 23. **Cresswell FV**, Ellis J, Hartley J, Sabin CA, Orkin C, Churchill DR. A systematic review of risk of HIV transmission through biting or spitting: implications for policy. *HIV Med*. 2018 Apr 23. PMID: 29687590
 24. **Cresswell FV**, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R, Meya D, Boulware DR, Elliott AM. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). *Wellcome Open Res*. 2018 Jul 10;3:83. PMID: 30175245 doi: 10.1200/JGO.17.00106.
 25. Duhig KE, Hezelgrave NL, Charantimath U, Karadiguddi CC, Mastiholi SS, Mungarwadi GM, Surur F, Yadeta L, Guchale Y, Mambo V, Chinkoyo S, Musonda T, Jere C, Vwalika B, Kopeka M, Chima M, Miti J, Best R, Clarke M, Kamara J, Conteh J, Sandi P, Sesay M, Momodou F, Wandabwa J, Ditai J, Odeke NM, **Nakimuli A**, Byamugisha J, Namakula D, Kalyowa N, Birungi D, Nakirijja E, Hill C, Greene G, Vixama A, Toussaint P, Makonyola G, Bukani D, Kachinjika M, Makwakwa J. Evaluation of a novel vital sign device to reduce maternal mortality and morbidity in low-resource settings: a mixed method feasibility study for the CRADLE-3 trial. *BMC Pregnancy Childbirth*. 2018 Apr 27;18(1):115. doi: 10.1186/s12884-018-1737-x.
 26. **Egesa M**, Lubyayi L, Jones FM, van Diepen A, Chalmers IW, Tukahebwa EM, **Bagaya BS**, Hokke CH, Hoffmann KF, Dunne DW, **Elliott AM**, Yazdanbakhsh M, Wilson S, **Cose S**. Antibody responses to *Schistosoma mansoni* schistosomula antigens. *Parasite Immunol*. 2018 Sep 21:e12591. PMID: 30239012
 27. **Egesa M**, Lubyayi L, Tukahebwa EM, **Bagaya BS**, Chalmers IW, Wilson S, Hokke CH, Hoffmann KF, Dunne DW, Yazdanbakhsh M, Labuda LA, **Cose S**. *Schistosoma mansoni* schistosomula antigens induce Th1/Pro-inflammatory cytokine responses. *Parasite Immunol*. 2018 Sep 21:e12592. PMID: 30239006
 28. El Ayadi AM, **Barageine J**, Korn A, **Kakaire O**, Turan J, **Obore S**, **Byamugisha J**, Lester F, Nalubwama H, Mwanje H, Tripathi V, Miller S. Trajectories of women's physical and psychosocial health following obstetric fistula repair in Uganda: a longitudinal study.

29. Ellis J, **Cresswell FV**, Joshua R, Kenneth S, Boulware DR. Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults. Open Forum Infect Dis. 2018 Aug 29;5(8):ofy193. PMID: 30182032
30. Fily F, Ayikobua E, **Ssemwanga D**, Nicholas S, Kaleebu P, Delaunay C, Pasquier E, Amoros Quiles I, Balkan S, Schramm B. HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line. Trop Med Int Health. 2018 Oct;23(10):1075-1083. PMID: 30058269
31. Gideon Alex Mugisa, **Paul Kiondo** and Imelda Namagembe. Single dose ceftriaxone and Metronidazole versus multiple doses for antibiotic prophylaxis at elective caesarean section in Mulago hospital: A randomized clinical trial. *AAS Open Research* 2018, 1:11.
32. Hamill MM, Mbazira KJ, **Kiragga AN**, Gaydos CA, Jett-Goheen M, Parkes-Ratanshi R, Manabe YC, Nakku-Joloba E, Rompalo A. Challenges of Rapid Plasma Reagin Interpretation in Syphilis Screening in Uganda: Variability in Nontreponemal Results Between Different Laboratories. Sex Transm Dis. 2018 Dec;45(12):829-833. PMID: 29944643
33. Hirose A, Alwy F, **Atuhairwe S**, Morris JL, Pembe AB, Kaharuza F, et al. Disentangling the contributions of maternal and fetal factors to estimate stillbirth risks for intrapartum adverse events in Tanzania and Uganda. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2018. <https://doi.org/10.1002/ijgo.12689>
34. Kansiime F, Adibaku S, Wamboga C, Idi F, **Kato CD**, Yamuah L, Vaillant M, Kioy D, Oliario P, Matovu E. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. Parasit Vectors. 2018 Feb 22;11(1):105. PMID:29471865
35. **Kayongo A**, Gonzalo-Gil E, Gümüşgöz E, Niwaha AJ, Semitala F, Kalyesubula R, **Bagaya BS**, Joloba ML, Sutton RE. Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda. J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):394-398. PMID: 30063647
36. Kenneth S, Bangdiwala AS, Kwizera R, Kandole TK, Tugume L, Kiggundu R, Mpoza E, Nuwagira E, Williams DA, Lofgren SM, Abassi M, Musubire AK, **Cresswell FV**, Rhein J, Muzoora C, Hullsiek KH, Boulware DR, Meya DB; ASTRO-CM team. Symptomatic cryptococcal antigenemia presenting as early cryptococcal meningitis with negative CSF analysis. Clin Infect Dis. 2018 Sep 25. PMID: 30256903
37. Kigozi E, Kasule GW, Musisi K, Lukoye D, **Kyobe S**, Katabazi FA, Wampande EM, Joloba ML, **Kateete DP**. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One. 2018 May 30;13(5):e0198091. PMID: 29847567
38. **Kimuda SG**, **Biraro IA**, **Bagaya BS**, Raynes JG, **Cose S**. Characterising antibody avidity in individuals of varied Mycobacterium tuberculosis infection status using surface plasmon resonance. PLoS One. 2018 Oct 12;13(10):e0205102. PMID: 30312318
39. Kotsakiozi P, Evans BR, Gloria-Soria A, Kamgang B, **Mayanja M**, Lutwama J, Le Goff G, Ayala D, Paupy C, Badolo A, Pinto J, Sousa CA, Troco AD, Powell JR. Population structure of a vector of human diseases: Aedes aegypti in its ancestral range, Africa. Ecol Evol. 2018 Jul 13;8(16):7835-7848. PMID: 30250667
40. Lukindu M, Bergey CM, Wiltshire RM, Small ST, Bourke BP, **Kayondo JK**, Besansky NJ. Spatio-temporal genetic structure of Anopheles gambiae in the Northwestern Lake Victoria Basin, Uganda: implications for genetic control trials in malaria endemic regions. Parasit Vectors. 2018 Apr 16;11(1):246. PMID: 29661226
41. **Lule SA**, **Elliott AM**, Smeeth L, Webb EL. Is birth weight associated with blood pressure among African children and adolescents? A systematic review. J Dev Orig Health Dis. 2018 Jun;9(3):270-280. PMID: 29353561
42. **Lule SA**, Namara B, Akurut H, Muhangi L, Lubyayi L, **Nampijja M**, Akello F, Tumusiime J, Aujo JC, Oduru G, Smeeth L, **Elliott AM**, Webb EL. Are birthweight and postnatal weight gain in childhood associated with blood pressure in early adolescence? Results from a Ugandan birth cohort. Int J Epidemiol. 2018 Jul 3. PMID: 29982658
43. Mabonga E, Parkes-Ratanshi R, Riedel S, **Nabweyambo S**, Mbabazi O, Taylor C, Gaydos C, Manabe YC. Complete ciprofloxacin resistance in gonococcal isolates in an urban Ugandan clinic: findings from a cross-sectional study. Int J STD AIDS. 2018 Nov 4;956462418799017. PMID: 30392463
44. Mayito J, Andia I, Belay M, Jolliffe DA, **Kateete DP**, Reece ST, Martineau AR. Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection. J Infect Dis. 2018 Oct 30. PMID: 30376080
45. Meya DB, **Kiragga AN**, Nalintya E, Morawski BM, Rajasingham R, Park BJ, Mubiru A, Kaplan JE, Manabe YC, Boulware DR; ORCAS study team. Reflexive laboratory-based cryptococcal antigen screening and preemptive fluconazole therapy for cryptococcal antigenemia in HIV-infected individuals with CD4 <100 cells/μL: a stepped-wedge, cluster-randomized trial. J Acquir Immune Defic Syndr. 2018 Nov 5. PMID: 30399034
46. Mezei AK, Pedersen HN, Sy S, Regan C, Mitchell-Foster SM, **Byamugisha J**, Miln JM and **Nakimuli A**. Medical complications in pregnancy at Mulago Hospital, Uganda's national referral hospital. Obstetric Medicine. 2018 Nov. 0(0) 1–7 doi: 10.1177/1753495X18805331.
47. Misra MK, Augusto DG, Martin GM, Nemat-Gorgani N, Sauter J, Hofmann JA, Traherne JA, González-Quezada B, Gorodezky C, Bultitude WP, Marin W, Vierra-Green C, Anderson KM, Balas A, Caro-Oleas JL, Cisneros E, Colucci F, Dandekar R, Elfshawi SM, Fernández-Viña MA, Fouda M, González-Fernández R, Große A, Herrero-Mata MJ, Hollenbach SQ, Marsh SGE, Mentzer A, Middleton D, Moffett A, Moreno-Hidalgo MA, Mossallam GI, **Nakimuli A**, Oksenberg JR, Oppenheimer SJ, Parham P, Petzl-Erler ML, Planelles D, Sánchez-García F, Sánchez-Gordo F, Schmidt AH, Trowsdale J, Vargas LB, Vicario JL, Vilches C, Norman PJ, Hollenbach JA. Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop. Hum Immunol. 2018 Oct 12.. PMID:30321631
48. Misra MK, Augusto DG, Montero Martin G, Nemat-Gorgani N, Sauter J, Hofmann JA, Traherne JA, González-Quezada

- B, Gorodezky C, Bultitude W, Marin W, Vierra-Green C, Anderson KM, Balas A, Caro-Oleas JL, Cisneros E, Colucci F, Dandekar R, Elfishawi S, Fernández-Viña MA, Fouda M, González-Fernández R, Große A, Herrero-Mata MJ, Hollenbach SQ, Marsh SG, Mentzer A, Middleton D, Moffett A, Moreno-Hidalgo MA, Mossallam G, **Nakimuli A**, Oksenberg JR, Oppenheimer SJ, Parham P, Petzl-Erler ML, Planelles D, Sánchez-García F, Sánchez-Gordo F, Schmidt AH, Trowsdale J, Vargas LB, Vicario JL, Vilches C, Norman PJ, Hollenbach JA. Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop. *Hum Immunol*. 2018 Oct 12. pii: S0198-8859(18)30925-X. doi: 10.1016/j.humimm.2018.10.003. [Epub ahead of print] Mitchell-Foster SM. Understanding Men's Perceptions of Human Papillomavirus and Moses E, Pedersen HN, Wagner EC, **Sekikubo M**, Money DM, Ogilvie GS, **Mpairwe H**, Amoah AS. Parasites and allergy: Observations from Africa. *Parasite Immunol*. 2018 Sep 14:e12589. PMID: 30216486
49. Mpimbaza A, Walakira A, Ndeez G, Katahoire A, Karamagi C, Nsoby SL, **Tukwasibwe S**, Asua V, Rosenthal PJ. Associations between erythrocyte polymorphisms and risks of uncomplicated and severe malaria in Ugandan children: A case control study. *PLoS One*. 2018 Sep 17;13(9):e0203229. PMID: 30222732
 50. Muriuki JM, Mentzer AJ, Kimita W, Ndungu FM, Macharia AW, Webb EL, **Lule SA**, Morovat A, Hill AVS, Bejon P, **Elliott AM**, Williams TN, Atkinson SH. Iron Status and Associated Malaria Risk Among African Children. *Clin Infect Dis*. 2018 Sep 14. PMID: 30219845
 51. Nabaggala MS, Parkes-Ratanshi R, Kasirye R, Kiragga A, Castlenuovo B, Ochaka I, Nakakawa L, Bena DA, Mujugira A. Re-engagement in HIV care following a missed visit in rural Uganda. *BMC Res Notes*. 2018 Oct 25;11(1):762. PMID: 30359290
 52. **Nabatanzi R**, **Cose S**, Joloba M, Jones SR, **Nakanjako D**. Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells. *AIDS Res Ther*. 2018 Mar 15;15(1):7. PMID: 29544508
 53. **Nalwoga A**, **Cose S**, Nash S, Miley W, Asiki G, Kusemererwa S, Yarchoan R, Labo N, Whitby D, Newton R. Relationship Between Anemia, Malaria Coinfection, and Kaposi Sarcoma-Associated Herpesvirus Seropositivity in a Population-Based Study in Rural Uganda. *J Infect Dis*. 2018 Aug 24;218(7):1061-1065. PMID: 29741631
 54. **Nalwoga A**, Miley W, Labo N, **Elliott A**, **Cose S**, Whitby D, Newton R. Age of Infection with Kaposi Sarcoma-Associated Herpesvirus and Subsequent Antibody Values Among Children in Uganda. *Pediatr Infect Dis J*. 2018 Aug;37(8):e225-e228. PMID: 29369149
 55. Nash S, Tittle V, Abaasa A, **Sanya RE**, Asiki G, Hansen CH, Grosskurth H, Kapiga S, Grundy C; Lake Victoria Consortium for Health Research. The validity of an area-based method to estimate the size of hard-to-reach populations using satellite images: the example of fishing populations of Lake Victoria. *Emerg Themes Epidemiol*. 2018 Aug 13;15:11. PMID: 30123310
 56. Nasuuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, **Nakanjako D**. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. *BMC Public Health*. 2018 Aug 22;18(1):1048. PMID: 30134880
 57. Neema S, Mongo Bua G, **Tuhebwe D**, Ssentongo J, Tumuhameye N, Mayega RW, Fishkin J, Atuyambe LM, Bazeyo W. Community Perspective on Policy Options for Resettlement Management: A Case Study of Risk Reduction in Bududa, Eastern Uganda. *PLoS Curr*. 2018 Jul 26;10. PMID: 30191081
 58. Newton R, Labo N, Wakeham K, Marshall V, Roshan R, **Nalwoga A**, Sebina I, Muhangi L, Webb EL, Miley W, Rochford R, **Elliott AM**, Whitby D. Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their Mothers. *J Infect Dis*. 2018 Aug 14;218(6):892-900. PMID: 29762709
 59. **Nkurungi G**, Kabagenyi J, **Nampijja M**, **Sanya RE**, Walusimbi B, Nassuuna J, Webb EL, **Elliott AM**; LaVIISWA study team. Schistosoma mansoni-specific immune responses and allergy in Uganda. *Parasite Immunol*. 2018 Jan;40(1). PMID: 29171863
 60. Nuwagaba-Biribonwoha H, **Kiragga AN**, Yiannoutsos CT, Musick BS, Wools-Kaloustian KK, Ayaya S, Wolf H, Lugina E, Ssali J, Abrams EJ, Elul B; International epidemiology Databases to Evaluate AIDS (IeDEA) East Africa Collaboration. Adolescent pregnancy at antiretroviral therapy (ART) initiation: a critical barrier to retention on ART. *J Int AIDS Soc*. 2018 Sep;21(9):e25178. PMID: 30225908
 61. Nyakato P, **Kiragga AN**, Kambugu A, Bradley J, Baisley K. Correction of estimates of retention in care among a cohort of HIV-positive patients in Uganda in the period before starting ART: a sampling-based approach. *BMJ Open*. 2018 Apr 20;8(4):e017487. PMID: 29678963
 62. Ojja S, Kisaka S, Edia M, **Tuhebwe D**, Kisakye AN, Halage AA, Mugambe RK, Mutyoba JN. Prevalence, intensity and factors associated with soil-transmitted helminths infections among preschool-age children in Hoima district, rural western Uganda. *BMC Infect Dis*. 2018 Aug 17;18(1):408. PMID: 30119650
 63. Otit-Senger J, Colebunders R, Reynolds SJ, Muwonge M, Nakigozi G, Kiggundu V, Nalugoda F, **Nakanjako D**. Elevated inflammatory cytokines in aqueous cytokine profile in HIV-1 infected patients with cataracts in Uganda. *BMC Ophthalmol*. 2018 Jan 19;18(1):12. PMID: 29351788
 64. Pembrey L, Barreto ML, Douwes J, Cooper P, Henderson J, **Mpairwe H**, Ardura-Garcia C, Chico M, Brooks C, Cruz AA, **Elliott AM**, Figueiredo CA, Langan SM, **Nassanga B**, Ring S, Rodrigues L, Pearce N. Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration. *ERJ Open Res*. 2018 Aug 22;4(3). PMID: 30151371
 65. Peters J, **Cresswell F**, Amor L, Cole K, Dean G, Didelot X, De Silva D, Eyre DW, Paul J. Whole genome sequencing of *Neisseria gonorrhoeae* reveals transmission clusters involving patients of mixed HIV serostatus. *Sex Transm Infect*. 2018 Mar;94(2):138-143. PMID: 29021406 PMID:30372572

66. Prentice S, Kamushaaga Z, Nash SB, **Elliott AM**, Dockrell HM, **Cose S**. Post-immunization leucocytosis and its implications for the management of febrile infants. *Vaccine*. 2018 May 11;36(20):2870-2875. PMID: 29655624
67. Retshabile G, Mlotshwa BC, Williams L, Mwesigwa S, Mboowa G, Huang Z, Rustagi N, Swaminathan S, Katagiry E, **Kyobe S**, Wayengera M, Kisitu GP, **Kateete DP**, Wampande EM, Maplanka K, Kasvosve I, Pettitt ED, Matshaba M, Nsangi B, Marape M, Tsimako-Johnstone M, Brown CW, Yu F, Kekitiinwa A, Joloba M, Mpoloka SW, Mardon G, Anabwani G, Hanchard NA; Collaborative African Genomics Network (CAfGEN) of the H3Africa Consortium. Whole-Exome Sequencing Reveals Uncaptured Variation and Distinct Ancestry in the Southern African Population of Botswana. *Am J Hum Genet*. 2018 May 3;102(5):731-743. PMID: 29706352
68. Ronald Wanyama, Gerald Obai, Pancras Odongo, **Mike N. Kagawa** and Rhona K. Baingana. Are women in Uganda gaining adequate gestational weight? A prospective study in low income urban Kampala. *Reproductive Health* (2018) 15:160 <https://doi.org/10.1186/s12978-018-0608-2>
69. **Sanya RE**, **Nkurunungi G**, Hoek Spaans R, **Nampijja M**, O'Hara G, Kizindo R, Oduru G, Kabuubi Nakawungu P, Niwagaba E, Abayo E, Kabagenyi J, Zziwa C, Nakazibwe E, Tumusiime J, Kaweesa J, Muwonge Kakooza F, Akello M, Lubyayi L, Verweij J, Nash S, van Ree R, **Mpairwe H**, **Tukahebwa E**, Webb EL, **Elliott AM**; LaVIISWA trial team. The impact of intensive versus standard anthelmintic treatment on allergy-related outcomes, helminth infection intensity and helminth-related morbidity in Lake Victoria fishing communities, Uganda: results from the LaVIISWA cluster randomised trial. *Clin Infect Dis*. 2018 Sep 8. PMID: 30202872
70. **Sekaggya-Wiltshire C**, **Lamorde M**, **Kiragga AN**, **Dooley KE**, **Kanya MR**, **Kambugu A**, **Fehr J**, **Manabe YC**, **Castelnuovo B**. The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. *Tuberculosis (Edinb)*. 2018 Jan;108:77-82. PMID: 29523331
71. **Sekikubo M**, Armstrong H, Rawat A, Singer J, Ogilvie GS, Kim JJ, Campos NG., Serwanga J, **Ssemwanga D**, Muganga M, Nakiboneka R, Nakubulwa S, Kiwuwa-Muyingo S, Morris L, Redd AD, Quinn TC, Kaleebu P; HIV Superinfection Study Group. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies. *Vaccine*. 2018 Jan 25;36(4):578-586. PMID:29274699
72. Sivo A, Schuetz A, Sheward D, Joag V, Yegorov S, Liebenberg LJ, Yende-Zuma N, Stalker A, Mwatelah RS, Selhorst P, Garrett N, Samsunder N, Balgobin A, Nawaz F, Cicala C, Arthos J, Fauci AS, Anzala AO, Kimani J, **Bagaya BS**, Kiwanuka N, Williamson C, Kaul R, Passmore JS, Phanuphak N, Ananworanich J, Ansari A, Abdool Karim Q, Abdool Karim SS, McKinnon LR; CAPRISA004 and RV254 study groups. Integrin $\alpha_4\beta_7$ expression on peripheral blood CD4⁺ T cells predicts HIV acquisition and disease progression outcomes. *Sci Transl Med*. 2018 Jan 24;10(425). PMID: 29367348
73. Ssemaganda A, Low LM, Verhoeft KR, Wambuzi M, Kawoozo B, Nabasumba SB, Mpendo J, **Bagaya BS**, Kiwanuka N, Stanisić DI, Berners-Price SJ, Good MF. Gold(i) phosphine compounds as parasite attenuating agents for malaria vaccine and drug development. *Metallomics*. 2018 Mar 1;10(3):444-454. PMID: 29465117
74. **Ssemwanga D**, Doria-Rose NA, Redd AD, Shiakolas AR, Longosz AF, **Nsubuga RN**, Mayanja BN, Asiki G, Seeley J, Kamali A, Ransier A, Darko S, Walker MP, Bruno D, Martens C, Douek D, Porcella SF, Quinn TC, Mascola JR, Kaleebu P. Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. *J Infect Dis*. 2018 Apr 23;217(10):1530-1534. PMID: 29579256
75. Stanley IJ, Kajumbula H, Bazira J, Kansime C, Rwego IB, **Asiimwe BB**. Multidrug resistance among Escherichia coli and Klebsiella pneumoniae carried in the gut of out-patients from pastoralist communities of Kasese district, Uganda. *PLoS One*. 2018 Jul 17;13(7):e0200093. PMID: 30016317
76. Stockdale L, Nash S, **Nalwoga A**, Painter H, Asiki G, Fletcher H, Newton R. Human cytomegalovirus epidemiology and relationship to tuberculosis and cardiovascular disease risk factors in a rural Ugandan cohort. *PLoS One*. 2018 Feb 6;13(2):e0192086. PMID: 29408860
77. Thorne L, **Nalwoga A**, Mentzer AJ, de Rougemont A, Hosmillo M, Webb E, **Nampijja M**, Muhwezi A, Carstensen T, Gurdasani D, Hill AV, Sandhu MS, **Elliott A**, Goodfellow I. The First Norovirus Longitudinal Seroepidemiological Study From Sub-Saharan Africa Reveals High Seroprevalence of Diverse Genotypes Associated With Host Susceptibility Factors. *J Infect Dis*. 2018 Jul 24;218(5):716-725. PMID: 29912471
78. Trop Med Int Health. 2018 Oct 29. doi: 10.1111/tmi.13178. [Epub ahead of print]Uganda: a cost-effectiveness analysis of the ASPIRE trial. *BMJ Open*. 2018 Jun vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and
79. Verma S, Du P, **Nakanjako D**, Hermans S, Briggs J, Nakiyingi L, Ellner JJ, Manabe YC, Salgame P. "Tuberculosis in advanced HIV infection is associated with increased expression of IFN γ and its downstream targets". *BMC Infect Dis*. 2018 May 15;18(1):220. PMID: 29764370
80. von Braun A, Sekaggya-Wiltshire C, Bachmann N, **Ssemwanga D**, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A. HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. *J Acquir Immune Defic Syndr*. 2018 Aug 15;78(5):566-573. PMID: 29771783
81. Vousden N, Lawley E, Nathan HL, Seed PT, Brown A, Muchengwa T, Charantimath U, Bellad M, Gidiri MF, Goudar S, Chappell LC, Sandall J, Shennan AH; **CRADLE Trial Collaborative Group**. Collaborators: (41)
82. Wadunde I, Mpimbaza A, Musoke D, Ssempebwa JC, Ediau M, **Tuhebwe D**, Adoke Y, Wanyenze RK. Factors associated with willingness to take up indoor residual spraying to prevent malaria in Tororo district, Uganda: a cross-sectional study. *Malar J*. 2018 Jan 5;17(1):5. PMID: 29304803
83. Wadunde I, **Tuhebwe D**, Ediau M, Okure G, Mpimbaza A, Wanyenze RK. Factors associated with adherence to antiretroviral therapy among HIV infected children in Kabale district, Uganda: a cross sectional study. *BMC Res Notes*. 2018 Jul 13;11(1):466. PMID: 30001748

84. Wayengera M, **Kateete DP**, **Asimwe B**, Joloba ML. [Mycobacterium tuberculosis thymidylate kinase antigen assays for designating incipient, high-risk latent M.tb infection](#). BMC Infect Dis. 2018 Mar 16;18(1):133. PMID: 29548281
85. Weissberg D, Mubiru F, Kambugu A, Fehr J, **Kiragga A**, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kanya M, Castelnovo B. [Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort](#). PLoS One. 2018 Nov 1;13(11):e0206796. PMID: 30383836
86. Wiltshire RM, Bergey CM, **Kayondo JK**, Birungi J, Mukwaya LG, Emrich SJ, Besansky NJ, Collins FH. [Reduced-representation sequencing identifies small effective population sizes of Anopheles gambiae in the north-western Lake Victoria basin, Uganda](#). Malar J. 2018 Aug 6;17(1):285. PMID: 30081911
87. Yegorov S, Galiwango RM, Good SV, Mpendo J, Tannich E, Boggild AK, Kiwanuka N, **Bagaya BS**, Kaul R. [Schistosoma mansoni infection and socio-behavioural predictors of HIV risk: a cross-sectional study in women from Uganda](#). BMC Infect Dis. 2018 Nov 19;18(1):586. PMID: 30453907
88. **Tweyongyere R**, **Nassanga BR**, Muhwezi A, Odongo M, Lule SA, Nsubuga RN, Webb EL, **Cose SC**, **Elliott AM** and the IMOCHI study team. Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles catch-up immunisation in pre-school children: a randomised trial. PLoS Negl Trop Dis, in press.
89. Tann CJ, Webb EL, Lassman R, Ssekya J, Sewagaba M, Musoke M, Burgoine K, Hagmann C, Deane-Bowers E, Norman K, Milln J, Kurinczuk JJ, **Elliott AM**, Martinez-Biarge M, Nakakeeto M, Robertson NJ, Cowan F. Early Childhood Outcomes After Neonatal Encephalopathy in Uganda: A Cohort Study. EClinicalMedicine in press. [
90. **Nampijja M**, Kizindo R, Apule B, **Lule S**, Muhangi L, Titman A, **Elliott A**, Alcock K, Lewis C. The role of the home environment in neurocognitive development of children living in extreme poverty and with frequent illnesses: a cross-sectional study [version 1; referees: awaiting peer review]. Wellcome Open Res 2018, 3:152 (<https://doi.org/10.12688/wellcomeopenres.14702.1>)
91. **Wajja A**, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, **Nassanga B**, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, **Cose S**, Levin J, Kaleebu P, Tukahebwa E, McShane H, **Elliott AM**. Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A [version 1; referees: awaiting peer review]. Wellcome Open Res 2018, 3:121 (doi: 10.12688/wellcomeopenres.14736.1)
92. Abaasa A, Asiki G, Obuku Ekii A, Wanyenze J, Pala P, van Dam GJ, Corstjens PLAM, Huges P, Pantaleo G, Kaleebu P, **Elliott AM***, Kamali A*. Effect of high-intensity versus low-intensity praziquantel treatment on HIV disease progression in HIV and Schistosoma mansoni co-infected patients: a randomised controlled trial. Wellcome Open Res 2018, 3:81 (doi: 10.12688/wellcomeopenres.14683.1). *Equal contribution.
93. **Elliott AM**, Roestenberg M, **Wajja A**, Opio C, Angumya F, Adriko M, **Egesa M**, Gitome S, Mfutso-Bengo J, Bejon P, Kapulu M, Seager Z, Lutalo T, Nazziwa WB, Muwumya A, Yazdanbakhsh M, Kaleebu P, Kabatereine N, Tukahebwa E. Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders' meeting held in Entebbe, Uganda. AAS Open Res 2018, 1:2 (doi: 10.12688/aasopenres.12841.1)
94. **Cummings MJ**, Tokarz R, **Bakamutumaho B**, Kayiwa J, Byaruhanga T, Owor N, Namagambo B, Wolf A, Mathema B, Lutwama JJ, Schluger NW, Lipkin W, O'Donnell MR., (2018). Precision Surveillance for Viral Respiratory Pathogens: Virome Capture Sequencing for the Detection. Clin Infect Dis. 2018 Aug 7

2017/18

1. Andrianakis I, Vernon I, McCreesh N, McKinley TJ, Oakley JE, **Nsubuga RN**, Goldstein M, White RG. [History matching of a complex epidemiological model of human immunodeficiency virus transmission by using variance emulation](#). J R Stat Soc Ser C Appl Stat. 2017 Aug;66(4):717-740. PMID:28781386
2. Asua V, **Tukwasibwe S**, Conrad M, Walakira A, Nankabirwa JJ, Mugenyi L, Kanya MR, Nsoby SL, Rosenthal PJ. [Plasmodium Species Infecting Children Presenting with Malaria in Uganda](#). Am J Trop Med Hyg. 2017 Sep;97(3):753-757. PMID:28990911
3. **Bagaya BS**, Tian M, Nickel GC, Vega JF, Li Y, He P, Klein K, Mann JFS, Jiang W, Arts EJ, Gao Y. [An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients](#). J Mol Biol. 2017 Jul 7;429(14):2246-2264. PMID:28472629
4. Bahr NC, Nuwagira E, Evans EE, **Cresswell FV**, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala AS, Meya DB, Denkinger CM, Muzoora C, Boulware DR; ASTRO-CM Trial Team. [Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study](#). Lancet Infect Dis. 2018 Jan;18(1):68-75. PMID: 28919338
5. Blokhuis JH, Hilton HG, Guethlein LA, Norman PJ, Nemat-Gorgani N, **Nakimuli A**, Chazara O, Moffett A, Parham P. [KIR2DS5 allotypes that recognize the C2 epitope of HLA-C are common among Africans and absent from Europeans](#). Immun Inflamm Dis. 2017 Dec;5(4):461-468. PMID: 28685972
6. Byakika-Kibwika P, Achan J, Lamorde M, Karera-Gonahasa C, **Kiragga AN**, Mayanja-Kizza H, Kiwanuka N, Nsoby S, Talisuna AO, Merry C. [Intravenous artesunate plus Artemisinin based Combination Therapy \(ACT\) or intravenous quinine plus ACT for treatment of severe malaria in Ugandan children: a randomized controlled clinical trial](#). BMC Infect Dis. 2017 Dec 28;17(1):794. PMID:29281988
7. Castelnovo B, Musomba R, Musaaizi J, **Kiragga AN**. [Different modalities of entry in a large urban clinic in Uganda and impact on outcomes of patients assessing HIV care and treatment](#). AIDS Care. 2017 Feb;29(2):259-262. PMID:27684099

8. Conrad MD, Mota D, Foster M, [Tukwasibwe S](#), Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. [Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda](#). *J Infect Dis*. 2017 Nov 15;216(8):1008-1017. PMID:28968782
9. Cose S. [The Yin and Yang of the Non-Specific Effects of Vaccines](#). *EBioMedicine*. 2017 Sep;23:8-9. PMID:28807515
10. Cresswell FV, Levett T. Specialist care of older adults with HIV infection in the UK: a service evaluation. *HIV Med*. 2017 Aug;18(7):519-524. PMID: 28117544
11. [Egesa M](#), Hoffmann KF, Hokke CH, Yazdanbakhsh M, [Cose S](#). [Rethinking Schistosomiasis Vaccine Development: Synthetic Vesicles](#). *Trends Parasitol*. 2017 Dec;33(12):918-921. PMID:28818406
12. Flynn AG, Anguzu G, Mubiru F, [Kiragga AN](#), Kamya M, Meya DB, Boulware DR, Kambugu A, Castelnuovo BC. [Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy](#). *PLoS One*. 2017 Dec 15;12(12):e0189055. PMID:29244807
13. Gurwitz KT, Aron S, Panji S, Maslamoney S, Fernandes PL, Judge DP, Ghouila A, Domelevo Entfellner JB, Guerfali FZ, Saunders C, Mansour Alzohairy A, Salifu SP, Ahmed R, Cloete R, [Kayondo J](#), [Ssemwanga D](#), Mulder N; H3ABioNet Consortium's Education Training and Working Group as members of the H3Africa Consortium. [Designing a course model for distance-based online bioinformatics training in Africa: The H3ABioNet experience](#). *PLoS Comput Biol*. 2017 Oct 5;13(10):e1005715. PMID:28981516
14. Hailemariam Z, Tuhebwe D, Park MM, Hall CD. [Unexplained haemorrhagic fever in Rural Ethiopia](#). *Pan Afr Med J*. 2017 May 28;27(Suppl 1):3. PMID:28721167
15. Hamill L, Picozzi K, Fyfe J, von Wissmann B, Wastling S, Wardrop N, Selby R, Acup CA, Bardosh KL, [Muhanguzi D](#), Kabasa JD, Waiswa C, Welburn SC. [Evaluating the impact of targeting livestock for the prevention of human and animal trypanosomiasis, at village level, in districts newly affected with T. b. rhodesiense in Uganda](#). *Infect Dis Poverty*. 2017 Feb 6;6(1):16. PMID:28162093
16. Hearps AC, Tyssen D, Srbnovski D, [Bayigga L](#), Diaz DJD, Aldunate M, Cone RA, Gugasyan R, Anderson DJ, Tachedjian G. [Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition](#). *Mucosal Immunol*. 2017 Nov;10(6):1480-1490. PMID:28401934
17. [Kateete DP](#), Nakanjako R, Okee M, Joloba ML, Najjuka CF. [Genotypic diversity among multidrug resistant Pseudomonas aeruginosa and Acinetobacter species at Mulago Hospital in Kampala, Uganda](#). *BMC Res Notes*. 2017 Jul 14;10(1):284. PMID:28705201
18. [Kimuda SG](#), [Nalwoga A](#), Levin J, Franken KL, Ottenhoff TH, [Elliott AM](#), [Cose S](#), [Andia-Biraro I](#). [Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of Mycobacterium tuberculosis in Individuals with Latent Tuberculosis Infection](#). *J Immunol Res*. 2017; PMID:28255560
19. [Kimuda SG](#), [Andia-Biraro I](#), [Egesa M](#), [Bagaya BS](#), Raynes JG, Levin J, [Elliott AM](#), [Cose S](#). [Use of QuantiFERON®-TB Gold in-tube culture supernatants for measurement of antibody responses](#). *PLoS One*. 2017 Nov 21; PMID:29161328
20. Kiwanuka N, Ssetaala A, Ssekandi I, Nalutaaya A, Kitandwe PK, Ssempiira J, [Bagaya BS](#), Balyegisawa A, Kaleebu P, Hahn J, Lindan C, Sewankambo NK. [Population attributable fraction of incident HIV infections associated with alcohol consumption in fishing communities around Lake Victoria, Uganda](#). *PLoS One*. 2017 Feb 16;12(2):e0171200. PMID:28207844
21. Kiwuwa-Muyingo S, Nazziwa J, [Ssemwanga D](#), Ilmonen P, Njai H, Ndembu N, Parry C, Kitandwe PK, Gershim A, Mpendo J, Neilsen L, Seeley J, Seppälä H, Lyagoba F, Kamali A, Kaleebu P. [HIV-1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda: A phylogenetic and epidemiological approach](#). *PLoS One*. 2017 Oct 12;12(10):e0185818. PMID:29023474
22. [Lule SA](#), [Mpairwe H](#), Nampijja M, Akello F, Kabagenyi J, Namara B, [Nkurunungi G](#), Kizito D, Kahwa J, Muhangi L, Nash S, Muwanga M, Webb EL, [Elliott AM](#). [Life-course of atopy and allergy-related disease events in tropical sub-Saharan Africa: A birth cohort study](#). *Pediatr Allergy Immunol*. 2017 Jun;28(4):377-383. PMID:28339128
23. Mawa PA, Webb EL, Filali-Mouhim A, Nkurunungi G, Sekaly RP, [Lule SA](#), Prentice S, Nash S, Dockrell HM, [Elliott AM](#), [Cose S](#). [Maternal BCG scar is associated with increased infant proinflammatory immune responses](#). *Vaccine*. 2017 Jan 5;35(2):273-282. PMID:27914741
24. McCreesh N, Andrianakis I, [Nsubuga RN](#), Strong M, Vernon I, McKinley TJ, Oakley JE, Goldstein M, Hayes R, White RG. [Universal test, treat, and keep: improving ART retention is key in cost-effective HIV control in Uganda](#). *BMC Infect Dis*. 2017 May 3;17(1):322. PMID:28468605
25. McCreesh N, Andrianakis I, [Nsubuga RN](#), Strong M, Vernon I, McKinley TJ, Oakley JE, Goldstein M, Hayes R, White RG. [Improving ART programme retention and viral suppression are key to maximising impact of treatment as prevention - a modelling study](#). *BMC Infect Dis*. 2017 Aug 9;17(1):557. PMID:28793872
26. Mlotshwa BC, Mwesigwa S, Mboowa G, Williams L, Retshabile G, Kekitiinwa A, Wayengera M, [Kyobe S](#), Brown CW, Hanchard NA, Mardon G, Joloba M, Anabwani G, Mpoloka SW. [The collaborative African genomics network training program: a trainee perspective on training the next generation of African scientists](#). *Genet Med*. 2017 Jul;19(7):826-833. PMID:28383545
27. [Muhanguzi D](#), Mugenyi A, Bigirwa G, Kamusiime M, Kitibwa A, Akurut GG, Ochwo S, Amanyire W, Okech SG, Hattendorf J, [Tweyongyere R](#). [African animal trypanosomiasis as a constraint to livestock health and production in Karamoja region: a detailed qualitative and quantitative assessment](#). *BMC Vet Res*. 2017 Nov 25;13(1):355. PMID:29178951
28. Muhumuza S, Akello E, Kyomugisha-Nuwagaba C, Baryamutuma R, Sebuliba I, Lutalo IM, Kansiime E, Kisaakye LN, [Kiragga AN](#), King R, Bazeyo W, Lindan C. [Retention in care among HIV-infected pregnant and breastfeeding](#)

- [women on lifelong antiretroviral therapy in Uganda: A retrospective cohort study.](#) *PLoS One*. 2017 Dec 22;12(12):e0187605. PMID:29272268
29. Musaazi J, Kiragga AN, Castelnovo B, Kambugu A, Bradley J, Rehman AM. [Tuberculosis treatment success among rural and urban Ugandans living with HIV: a retrospective study.](#) *Public Health Action*. 2017 Jun 21;7(2):100-109. PMID:28695082
 30. Musomba R, Mubiru F, Nakalema S, Mackline H, Kalule I, Kiragga AN, Ratanshi RP, Castelnovo B. [Describing Point of Entry into Care and Being Lost to Program in a Cohort of HIV Positive Pregnant Women in a Large Urban Centre in Uganda.](#) *AIDS Res Treat*. 2017;2017:3527563. PMID:28469942
 31. Nabweyambo S, Kakaire O, Sowinski S, Okeng A, Ojiambo H, Kimeze J, Najjingo I, Bwanga F. [Very low sensitivity of wet mount microscopy compared to PCR against culture in the diagnosis of vaginal trichomoniasis in Uganda: a cross sectional study.](#) *BMC Res Notes*. 2017 Jul 6;10(1):259. PMID:28683790
 32. Nakanjako D, Akena D, Kaye DK, Tumwine J, Okello E, Nakimuli A, Kambugu A, McCullough H, Mayanja-Kizza H, Kamya MR, Sewankambo NK. [A need to accelerate health research productivity in an African University: the case of Makerere University College of Health Sciences.](#) *Health Res Policy Syst*. 2017 Apr 21;15(1):33. PMID:28431554
 33. Namara B, Nash S, Lule SA, Akurut H, Mpairwe H, Akello F, Tumusiime J, Kizza M, Kabagenyi J, Nkurunungi G, Muhangi L, Webb EL, Muwanga M, Elliott AM. [Effects of treating helminths during pregnancy and early childhood on risk of allergy-related outcomes: Follow-up of a randomized controlled trial.](#) *Pediatr Allergy Immunol*. 2017 Dec;28(8):784-792. PMID:28892575
 34. Nash S, Mentzer AJ, Lule SA, Kizito D, Smits G, van der Klis FR, Elliott AM. [The impact of prenatal exposure to parasitic infections and to anthelmintic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial.](#) *PLoS Negl Trop Dis*. 2017 Feb 8;11(2):e0005213. PMID:28178298
 35. Nkurunungi G, Kabagenyi J, Nampijja M, Sanya RE, Walusimbi B, Nassuuna J, Webb EL, Elliott AM; LaVIISWA study team. [Schistosoma mansoni-specific immune responses and allergy in Uganda.](#) *Parasite Immunol*. 2018 Jan;40(1). PMID:29171863
 36. Okee M, Bayiyana A, Musubika C, Joloba ML, Ashaba-Katabazi F, Bagaya B, Wayengera M. [In Vitro Transduction and Target-Mutagenesis Efficiency of HIV-1 pol Gene Targeting ZFN and CRISPER/Cas9 Delivered by Various Plasmids and/or Vectors: Toward an HIV Cure.](#) *AIDS Res Hum Retroviruses*. 2018 Jan 5. PMID:29183134
 37. Okuni JB, Kateete DP, Okee M, Nanteza A, Joloba M, Ojok L. [Application of antibodies to recombinant heat shock protein 70 in immunohistochemical diagnosis of mycobacterium avium subspecies paratuberculosis in tissues of naturally infected cattle.](#) *Ir Vet J*. 2017 Mar 24;70:10. PMID:28344769
 38. Osingada CP, Okuga M, Nabirye RC, Sewankambo NK, Nakanjako D. [Disclosure of Parental HIV Status to Children: Experiences of Adults Receiving Antiretroviral Treatment at an Urban Clinic in Kampala, Uganda.](#) *AIDS Res Treat*. 2017;2017:3458684. PMID:29209538
 39. Ratmann O, Wymant C, Colijn C, Danaviah S, Essex M, Frost SDW, Gall A, Gaiseitsiwe S, Grabowski M, Gray R, Guindon S, von Haeseler A, Kaleebu P, Kendall M, Kozlov A, Manasa J, Minh BQ, Moyo S, Novitsky V, Nsubuga R, Pillay S, Quinn TC, Serwadda D, Ssemwanga D, Stamatakis A, Trifinopoulos J, Wawer M, Leigh Brown A, de Oliveira T, Kellam P, Pillay D, Fraser C. [HIV-1 full-genome phylogenetics of generalized epidemics in sub-Saharan Africa: impact of missing nucleotide characters in next-generation sequences.](#) *AIDS Res Hum Retroviruses*. 2017 May 25. PMID:28540766
 40. Sanya RE, Tumwesige E, Elliott AM, Seeley J. [Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda.](#) *PLoS Negl Trop Dis*. 2017 Oct 2;11(10). PMID:28968470
 41. Sanya RE, Nkurunungi G, Andia Biraro I, Mpairwe H, Elliott AM. [A life without worms.](#) *Trans R Soc Trop Med Hyg*. 2017 Jan 1;111(1):3-11. PMID:28340138
 42. Semeere AS, Castelnovo B, Bbaale DS, Kiragga AN, Kigozi J, Muganzi AM, Coutinho AG, Kambugu A. [Innovative Demand Creation for Voluntary Medical Male Circumcision Targeting a High Impact Male Population: A Pilot Study Engaging Pregnant Women at Antenatal Clinics in Kampala, Uganda.](#) *J Acquir Immune Defic Syndr*. 2016 Aug 15;72. PMID:27404008
 43. Serwanga J, Ssemwanga D, Muganga M, Nakiboneka R, Nakubulwa S, Kiwuwa-Muyingo S, Morris L, Redd AD, Quinn TC, Kaleebu P; HIV Superinfection Study Group. [HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.](#) *Vaccine*. 2017 Dec 20. PMID:29274699
 44. Ssengooba W, Lukoye D, Meehan CJ, Kateete DP, Joloba ML, de Jong BC, Cobelens FG, van Leth F. [Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda.](#) *Int J Tuberc Lung Dis*. 2017 May 1;21(5):531-536. PMID:28399968
 45. Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CVA, James RM, Egesa M, Cose S, Lutwama JJ, Lobel L, Dye JM. [Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.](#) *J Exp Med*. 2017 Sep 4;214(9):2563-2572. PMID:28724616
 46. Tann CJ, Nakakeeto M, Willey BA, Sewegaba M, Webb EL, Oke I, Mutuza ED, Peebles D, Musoke M, Harris KA, Sebire NJ, Klein N, Kurinczuk JJ, Elliott AM, Robertson NJ. [Perinatal risk factors for neonatal encephalopathy: an unmatched case-control study.](#) *Arch Dis Child Fetal Neonatal Ed*. 2017 Aug 5. PMID:28780500
 47. Tukwasibwe S, Tumwebaze P, Conrad M, Arinaitwe E, Kamya MR, Dorsey G, Nsobya SL, Greenhouse B, Rosenthal PJ. [Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda.](#) *Malar J*. 2017 Mar 21;16(1):125. PMID:28327148
 48. Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V, Walakira A, Nankabirwa J, Yeka A, Staedke SG, Greenhouse B, Nsobya SL, Kamya MR, Dorsey G, Rosenthal PJ. [Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda.](#) *J Infect Dis*. 2017 Feb 15;215(4):631-635. PMID:28039354

49. Tushemereirwe R, [Tuhebwe D](#), Cooper MA, D'ujanga FM. [The Most Effective Methods for Delivering Severe Weather Early Warnings to Fishermen on Lake Victoria](#). *PLoS Curr*. 2017 Feb 22;9. PMID:28480125
50. [Wajja A](#), Kizito D, [Nassanga B](#), Nalwoga A, Kabagenyi J, [Kimuda S](#), Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, [Cose S](#), Levin J, Kaleebu P, [Elliott AM](#), McShane H. [The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial](#). *PLoS Negl Trop Dis*. 2017 May 4;11(5):e0005440. PMID:28472067
51. Wadunde I, Mpimbaza A, Musoke D, Ssempebwa JC, Ediau M, [Tuhebwe D](#), Adoke Y, Wanyenze RK. [Factors associated with willingness to take up indoor residual spraying to prevent malaria in Tororo district, Uganda: a cross-sectional study](#). *Malar J*. 2018 Jan 5;17(1):5. PMID:29304803
52. Walakira A, [Tukwasibwe S](#), Kiggundu M, Verra F, Kakeeto P, Ruhamyankaka E, Drakeley C, Dorsey G, Kamya MR, Nsobya SL, Rosenthal PJ. [Marked variation in prevalence of malaria-protective human genetic polymorphisms across Uganda](#). *Infect Genet Evol*. 2017 Nov;55:281-287. PMID:28939159
53. Wanyama JN, Nabaggala MS, Wandera B, [Kiragga AN](#), Castelnovo B, Mambule IK, Nakajubi J, Kambugu AD, Paton NI, Wanyenze RK, Colebunders R, Easterbrook P. [Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial](#). *Int J STD AIDS*. 2017 Jan. PMID:28814161
54. Wayengera M, Mwebaza I, Welishe J, Nakimuli C, [Kateete DP](#), Wampande E, Kirimunda S, [Bayigga L](#), Musubika C, Babirye P, Asimwe B, Joloba ML. [Sero-diagnosis of Active Mycobacterium tuberculosis Disease among HIV Co-infected Persons using Thymidylate Kinase based Antigen and Antibody Capture Enzyme Immuno-Assays](#). *Mycobact Dis*. 2017 Jun;7(2). PMID:28856068
55. Wayengera M, Mwebaza I, Welishe J, Bayiyana A, [Kateete DP](#), Wampande E, Kirimunda S, Kigozi E, Katabazi F, Musubika C, [Kyobe S](#), Babirye P, [Asimwe B](#), Joloba ML. [Immuno-diagnosis of Mycobacterium tuberculosis in sputum, and reduction of timelines for its positive cultures to within 3 h by pathogen-specific thymidylate kinase expression assays](#). *BMC Res Notes*. 2017 Aug 8;10(1):368. PMID:2878970

2016

1. [Kimuda SG](#), [Nalwoga A](#), Levin J, Franken KLMC, Ottenhoff THM, [Elliott AM](#), [Cose S](#), [Andia-Biraro I](#). Humoral responses to Rv1733c, Rv0081, Rv1735c and Rv1737c DosR regulon-encoded proteins of Mycobacterium tuberculosis in individuals with latent tuberculosis infection. *Journal of Immunological Research*, in press.
2. Nash S, Mentzer AJ, [Lule SA](#), Kizito D, van der Klis FRM, [Elliott AM](#). The impact of prenatal exposure to parasitic infections and to anthelmintic treatment on antibody responses to routine immunisations given in infancy: secondary analysis of a randomised controlled trial. *PLoS Neglected Tropical Diseases*, in press.
3. Amongin D, [Nakimuli A](#), Busingye R, Mubiru M, Musoke P, Mutyaba T. Effect of subsequent pregnancies on HIV disease progression among women in the Mulago Hospital MTCT-Plus program in Uganda. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics* 2016; 132(3): 347-52.
4. [Asimwe BB](#), Baldan R, Trovato A, Cirillo DM. Molecular epidemiology of Pantone-Valentine Leukocidin-positive community-acquired methicillin resistant Staphylococcus aureus isolates in pastoral communities of rural south western Uganda. *BMC infectious diseases* 2017; 17(1): 24.
5. [Biraro IA](#), [Kimuda S](#), [Egesa M](#), [Cose S](#), Webb EL, Joloba M, Smith SG, [Elliott AM](#), Dockrell HM, Katamba A. The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda. *PLoS one* 2016; 11(1): e0146098.
6. Castelnovo B, [Kiragga A](#), Mubiru F, Kambugu A, Kamya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naive adults started on treatment in Uganda. *Journal of the International AIDS Society* 2016; 19(1): 20773.
7. Castelnovo B, Musomba R, Musaazi J, [Kiragga AN](#). Different modalities of entry in a large urban clinic in Uganda and impact on outcomes of patients assessing HIV care and treatment. *AIDS care* 2017; 29(2): 259-62.
8. de St Maurice A, Nyakarahuka L, Purpura L, Ervin E, Tumusiime A, Balinandi S, [Kayondo J](#), Mulei S, Namutebi AM, Tusiime P, Wiersma S, Nichol S, Rollin P, Klena J, Knust B, Shoemaker T. Notes from the Field: Rift Valley Fever Response - Kabale District, Uganda, March 2016. *MMWR Morbidity and mortality weekly report* 2016; 65(43): 1200-1.
9. Kasule GW, [Kateete DP](#), Joloba ML. Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families. *BMC infectious diseases* 2016; 16: 173.
10. Kateera F, Nsobya SL, [Tukwasibwe S](#), Hakizimana E, Mutesa L, Mens PF, Grobusch MP, van Vugt M, Kumar N. Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. *Acta tropica* 2016; 164: 329-36.
11. Kateera F, Nsobya SL, [Tukwasibwe S](#), Mens PF, Hakizimana E, Grobusch MP, Mutesa L, Kumar N, van Vugt M. Malaria case clinical profiles and Plasmodium falciparum parasite genetic diversity: a cross sectional survey at two sites of different malaria transmission intensities in Rwanda. *Malaria journal* 2016; 15: 237.
12. [Kateete DP](#), Nakanjako R, Namugenyi J, Erume J, Joloba ML, Najjuka CF. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007-2009). *SpringerPlus* 2016; 5(1): 1308.
13. [Kiragga AN](#), Nalintya E, Morawski BM, Kigozi J, Park BJ, Kaplan JE, Boulware DR, Meya DB, Manabe YC. Implementation and Operational Research: Impact of Nurse-Targeted Care on HIV Outcomes Among Immunocompromised Persons: A Before-After Study in Uganda. *Journal of acquired immune deficiency syndromes (1999)* 2016; 72(2): e32-6.

14. [Kitayimbwa JM](#), Mugisha JY, Saenz RA. Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains. *Theoretical population biology* 2016; 112: 33-42.
15. Luty AJ, [Elliott AM](#). Tackling neglect: treating schistosomiasis in pregnancy. *The Lancet Infectious diseases* 2016; 16(2): 137-9.
16. Mawa PA, Webb EL, Filali-Mouhim A, [Nkurunungi G](#), Sekaly RP, [Lule SA](#), Prentice S, Nash S, Dockrell HM, [Elliott AM](#), [Cose S](#). Maternal BCG scar is associated with increased infant proinflammatory immune responses. *Vaccine* 2017; 35(2): 273-82.
17. Monroe-Wise A, Mashalla Y, O'Malley G, Nathanson N, Seloilwe E, Gachuno O, Odero T, [Nakanjako D](#), Sewankambo N, Tarimo E, Urassa D, Manabe YC, Chapman S, Voss JG, Wasserheit J, Farquhar C. Training tomorrow's leaders in global health: impact of the Afya Bora Consortium Fellowship on the careers of its alumni. *BMC medical education* 2016; 16(1): 241.
18. Mulder NJ, Adebisi E, Alami R, Benkahla A, Brandful J, Doumbia S, Everett D, Fadlilmola FM, Gaboun F, Gaseitsiwe S, Ghazal H, Hazelhurst S, Hide W, Ibrahim A, Jaufeerally Fakim Y, Jongeneel CV, Joubert F, Kassim S, [Kayondo J](#), Kumuthini J, Lyantagaye S, Makani J, Mansour Alzohairy A, Masiga D, Moussa A, Nash O, Ouwe Missi Oukem-Boyer O, Owusu-Dabo E, Panji S, Patterson H, Radouani F, Sadki K, Seghrouchni F, Tastan Bishop O, Tiffin N, Ulenga N. H3ABioNet, a sustainable pan-African bioinformatics network for human heredity and health in Africa. *Genome research* 2016; 26(2): 271-7.
19. Najjuka CF, [Kateete DP](#), Kajumbula HM, Joloba ML, Essack SY. Antimicrobial susceptibility profiles of *Escherichia coli* and *Klebsiella pneumoniae* isolated from outpatients in urban and rural districts of Uganda. *BMC research notes* 2016; 9: 235.
20. [Nakanjako D](#), [Kiragga AN](#), Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, Oyaro P, Lugina E, Ssali JC, Kambugu A, Easterbrook P. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. *AIDS (London, England)* 2016; 30(12): 1913-22.
21. [Nakimuli A](#), Nakubulwa S, Kakaire O, Osinde MO, Mbalinda SN, Kakande N, Nabirye RC, Kaye DK. The burden of maternal morbidity and mortality attributable to hypertensive disorders in pregnancy: a prospective cohort study from Uganda. *BMC pregnancy and childbirth* 2016; 16: 205.
22. [Nakimuli A](#), Nakubulwa S, Kakaire O, Osinde MO, Mbalinda SN, Nabirye RC, Kakande N, Kaye DK. Maternal near misses from two referral hospitals in Uganda: a prospective cohort study on incidence, determinants and prognostic factors. *BMC pregnancy and childbirth* 2016; 16: 24.
23. Nakku-Joloba E, [Kiragga A](#), Mbazira JK, Kambugu F, Jett-Goheen M, Ratanshi RP, Gaydos C, Manabe YC. Clinical Evaluation of 2 Point-of-Care Lateral Flow Tests for the Diagnosis of Syphilis. *Sexually transmitted diseases* 2016; 43(10): 623-5.
24. Nankabirwa JI, Conrad MD, Legac J, [Tukwasibwe S](#), Tumwebaze P, Wandera B, Brooker SJ, Staedke SG, Kanya MR, Nsobya SL, Dorsey G, Rosenthal PJ. Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for *Plasmodium falciparum* Transporter Polymorphisms That Modify Drug Sensitivity. *Antimicrobial agents and chemotherapy* 2016; 60(10): 5649-54.
25. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, Corstjens PL, Joloba M, Ding S, Mpendo J, Nielsen L, Kamali A, [Elliott AM](#), Pantaleo G, Kaleebu P, Pala P. Effect of *Schistosoma mansoni* Infection on Innate and HIV-1-Specific T-Cell Immune Responses in HIV-1-Infected Ugandan Fisher Folk. *AIDS research and human retroviruses* 2016; 32(7): 668-75.
26. O'Hara GA, [Elliott AM](#). HIV and Helminths - Not All Worms Created Equal? *Trends in parasitology* 2016.
27. Osiigada CP, Okuga M, Nabirye RC, Sewankambo NK, [Nakanjako D](#). Prevalence, barriers and factors associated with parental disclosure of their HIV positive status to children: a cross-sectional study in an urban clinic in Kampala, Uganda. *BMC public health* 2016; 16: 547.
28. Osuret J, Atuyambe LM, Mayega RW, Ssentongo J, Tumuhameye N, Mongo Bua G, [Tuhebwe D](#), Bazeyo W. Coping Strategies for Landslide and Flood Disasters: A Qualitative Study of Mt. Elgon Region, Uganda. *PLoS currents* 2016; 8.
29. Semeere AS, Castelnovo B, Bbaale DS, [Kiragga AN](#), Kigozi J, Muganzi AM, Coutinho AG, Kambugu A. Innovative Demand Creation for Voluntary Medical Male Circumcision Targeting a High Impact Male Population: A Pilot Study Engaging Pregnant Women at Antenatal Clinics in Kampala, Uganda. *Journal of acquired immune deficiency syndromes (1999)* 2016; 72 Suppl 4: S273-9.
30. Sempa JB, Dushoff J, Daniels MJ, Castelnovo B, [Kiragga AN](#), Nieuwoudt M, Bellan SE. Reevaluating Cumulative HIV-1 Viral Load as a Prognostic Predictor: Predicting Opportunistic Infection Incidence and Mortality in a Ugandan Cohort. *American journal of epidemiology* 2016; 184(1): 67-77.
31. Sobarzo A, Stonier SW, Herbert AS, Ochayon DE, Kuehne AI, Eskira Y, Fedida-Metula S, Tali N, Lewis EC, [Egesa M](#), [Cose S](#), Lutwama JJ, Yavelsky V, Dye JM, Lobel L. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors. *Viruses* 2016; 8(5).
32. Tann CJ, Nakakeeto M, Hagmann C, Webb EL, Nyombi N, Namiro F, Harvey-Jones K, Muhumuza A, Burgoine K, [Elliott AM](#), Kurinczuk JJ, Robertson NJ, Cowan FM. Early cranial ultrasound findings among infants with neonatal encephalopathy in Uganda: an observational study. *Pediatric research* 2016; 80(2): 190-6.
33. Tumwebaze P, [Tukwasibwe S](#), Taylor A, Conrad M, Ruhamyankaka E, Asua V, Walakira A, Nankabirwa J, Yeka A, Staedke SG, Greenhouse B, Nsobya SL, Kanya MR, Dorsey G, Rosenthal PJ. Changing antimalarial drug resistance patterns identified by surveillance at three sites in Uganda. *The Journal of infectious diseases* 2016.
34. [Tweyongyere R](#), [Namanya H](#), [Naniima P](#), [Cose S](#), Tukahebwa EM, [Elliott AM](#), Dunne DW, Wilson S. Human eosinophils modulate peripheral blood mononuclear cell response to *Schistosoma mansoni* adult worm antigen in vitro. *Parasite immunology* 2016; 38(8): 516-22.
35. Vudriko P, Okwee-Acai J, Tayebwa DS, Byaruhanga J, Kakooza S, Wampande E, Omara R, Muhindo JB, [Tweyongyere R](#), Owiny DO, Hattat T, Tsuji N, Umemiya-Shirafuji R, Xuan X, Kanameda M, Fujisaki K, Suzuki H. Emergence of multi-acaricide resistant *Rhipicephalus* ticks and its implication on chemical tick control in Uganda. *Parasites & vectors* 2016; 9: 4.

36. Wanduru P, Tetui M, Tuhebwe D, Ediau M, Okuga M, Nalwadda C, Ekirapa-Kiracho E, Waiswa P, Rutebemberwa E. The performance of community health workers in the management of multiple childhood infectious diseases in Lira, northern Uganda - a mixed methods cross-sectional study. *Global health action* 2016; 9: 33194.
37. Webb EL, Nampijja M, Kaweesa J, Kizindo R, Namutebi M, Nakazibwe E, Oduru G, Kabubi P, Kabagenyi J, Nkurunungi G, Kizito D, Muhangi L, Akello M, Verweij JJ, Nerima B, Tukahebwa E, Elliott AM. Helminths are positively associated with atopy and wheeze in Ugandan fishing communities: results from a cross-sectional survey. *Allergy* 2016; 71(8): 1156-69.
38. Yegorov S, Galiwango RM, Ssemaganda A, Muwanga M, Wesonga I, Miiro G, Drajole DA, Kain KC, Kiwanuka N, Bagaya BS, Kaul R. Low prevalence of laboratory-confirmed malaria in clinically diagnosed adult women from the Wakiso district of Uganda. *Malaria journal* 2016; 15(1): 555.

Appendix 3. MUII fellows, past and present

[Current fellows highlighted in orange, completed fellowships highlighted in green]

Forename	Award dates	Research area/focus	Funding	Current position
Group Leaders, current				
Annettee Nakimuli	2017-2020	Pre-eclampsia	MUII-plus	Associate Professor, Dean, School of Medicine; immediate past Head of Department of Obstetrics & Gynaecology, Makerere CHS
Damalie Nakanjako	2017-2020	HIV and immune activation	MUII-plus	Professor, Principal Makerere College of health Sciences, immediate past Dean, School of Medicine
Benon Asiimwe	2017-2020	Anti-microbial resistance	MUII-plus	Associate Professor, Makerere CHS
PhD students, current				
Beatrice Nassanga	2019-2020	Tuberculosis vaccine immunogenicity	MUII/MRC	PhD student
Bridgious Walusimbi	2019-2022	Helminths, microbiome and metabolism	Royal Society	PhD student
Grace Nabakooza	2018-2021	Modelling the Transmission Dynamics of Avian Influenza in Africa with unbiased sampling	MUII-plus	PhD student
Stella Atim	2018-2021	Crimean-Congo haemorrhagic fever and other emerging tick-borne viral infections in Uganda.	MUII-plus	PhD student
Rita Mwima	2018-2021	Mosquito dynamics	Open Philanthropy Project Fund, an advised fund of Silicon Valley Community Foundation*	PhD student
Zac Anywaine	2018-2021	Rift Valley Fever	UK NIHR *	PhD student
Martin Mayanja	2017-2020	Characterisation and vector competence of rhabdoviruses in Arua and Kasese districts in Uganda.	MUII-plus	PhD student
Jacobs Iramiot	2017-2019	Under Benon Asiimwe's Group Leader Award	MUII-plus	PhD student
Sheila Nabweyambo	2017-2019	Under Annettee Nakimuli's Group Leader Award	MUII-plus	PhD student
Richard Sanya	2017-2019	The effect of helminth infection on insulin resistance and type 2 diabetes in rural and urban Uganda	MUII-plus	PhD student
Samuel Kyobe	2017-2019	Role of HLA Alleles in HIV Disease Progression in two African Paediatric Population	MUII-plus	PhD student
Stephen Tukwasibwe	2016-2019	Role of Killer cell Immunoglobulin-like Receptor and Human Leukocyte Antigen	MUII-plus	PhD student

Forename	Award dates	Research area/focus	Funding	Current position
		Polymorphisms in Transmission and Severity of Malaria in Uganda		
Lois Bayigga	2016-2019	Immuno-Modulation of Host Susceptibility to HIV Infection in the female Genital Tract: The Role of Microbiota	MUII-plus	PhD student
Fiona Cresswell	2017-2020	Tuberculous meningitis	Wellcome Trust	PhD student
Annet Nanvubya	2017-2020	HIV research	IAVI*	PhD student
Anne Wajja	2016-2017	Tuberculosis vaccines	MRC *	PhD student
Angela Nalwoga	2016-2019	Kaposi's Sarcoma Herpes Virus	APCDR*	PhD student
Gyaviira Nkurunungi	2016-2019	Helminths and allergy	APCDR*	PhD student
Masters students, current				
Joy Kabagenyi	2019-2021	Bioinformatics	EANBiT*/ MUII	Masters student (supplementary funding from MUII)
John Vianney Tushabe	2018-2019	Bioinformatics	Wellcome Trust Sanger Institute* / MUII	Masters student (supplementary funding)
Saudah Namubiru	2018-2019	MMED: Group B streptococcal colonization as a risk factor for poor neonatal outcomes among pregnant women in labour at Mulago Hospital	MUII-plus	Masters student
Pritch Kabata	2018-2019	MMED: The role of IL-7 on Phagocytosis among patients with sepsis in Mulago Hospital	MUII-plus	Masters student
Ivan Sserwadda	2019-2020	Characterization of accessory genomes of methicillin-resistant staphylococcus aureus isolates from inpatients attending the orthopedic ward of mulago hospital	MUII-plus/BReCA	Masters student
Edward Lukyamuzi	2019-2020	Assessing genetic differentiation and structure of Anopheles gambiae mosquito populations in Uganda from whole genome sequence analysis	MUII-plus/BReCA	Masters student
Ritah Nabunje	2019-2020	In Silico Characterisation of Variations in the HBB Gene and its Regulatory Regions in African Populations: Elucidating Genetic Risk for Hemoglobinopathies and Malaria	MUII-plus/BReCA	Masters student
Post-doctoral fellows, completed				
Irene Biraro	2016-2018	The Link between Tuberculosis Infection and Type-2 Diabetes Mellitus: Contribution of Innate Lymphoid Cells	MUII-plus	Senior Lecturer, Department of Medicine, Makerere CHS
David Kateete	2016-2018	Prevalence and Implications of Mixed <i>Mycobacterium tuberculosis</i> Infections in Uganda	MUII-plus	Lecturer and Acting Head of Department of Immunology and Molecular Biology, Makerere CHS
John Kitayimbwa	2016-2018	Uncovering Fine Scale Transmission Dynamics in a Heterogeneous Ugandan Population Using Molecular	MUII-plus	Lecturer, Department of Mathematics, CONAS

Forename	Award dates	Research area/focus	Funding	Current position
		Phylodynamic and Phylogeographic Methods		
Dennis Muhanguzi	2017-2018	<i>Trypanosoma brucei sensu lato</i> (s.l.) drug resistance: A roaming impediment to 2030 sleeping sickness eradication plan	MUII-plus	Assistant Lecturer, Makerere, COVAB
Charles Kato Drago	2016-2018	Clinical Validation of Novel Stage Diagnostic Biomarkers among <i>Trypanosoma brucei rhodesiense</i> Sleeping Sickness Patients in Uganda	MUII-plus	Assistant Lecturer, Makerere Department of Bio-Molecular Resources and Biolab Sciences, COVAB
Annettee Nakimuli	2013-2015	The Role of Killer immunoglobulin-like receptor (KIR) and HLA-C genes in Pre-eclampsia in an African population	MUII	Head of Department of Obstetrics & Gynaecology, Makerere CHS
Maggie Nampijja	2014-2016	Investigating growth and cognitive benefits of intensive versus annual anthelmintic treatment in children living in a heavily infected community	MUII	Scientist, MRC/UVRI
Damalie Nakanjako	2011-2013	Optimizing immune recovery among HAART-treated adults in an African cohort	MUII	Deputy Dean, School of Medicine, Makerere CHS
Deo Ssemwanga	2012-2014	The Virological and Immunological Correlates of HIV-1 superinfection among HIV-1 infected subtype discordant partners and female sex workers in Uganda	MUII	Senior Scientist, EDCTP Career Development Fellow, MRC/UVRI
Harriet Mpairwe	2012-2014	Study on Asthma	MUII	Senior Scientist, Wellcome Trust Training Fellow, MRC/UVRI
Robert Tweyongyere	2009-2011	Examining Immunoregulatory mechanisms in <i>Schistosoma mansoni</i> infection: the effector mechanisms of eosinophils	MUII	Dean, School of Veterinary Medicine, Makerere COVAB
Jonathan Kayondo	2009-2011	Emergence of Nevirapine resistance arising after treatment cessation and/or during successive structured treatment interruption (STI) in a rural and urban setting and development of assays to detect minority population	MUII	Senior Research Officer, UVRI
Agnes Kiragga [§]	2014-2015	Statistics; HIV	MUII	Head of Statistics, Infectious Diseases Institute, Makerere CHS
John Kitayimbwa [§]	2014-2015	Mathematics; HIV	MUII	Lecturer, Department of Mathematics, Makerere CONAS
Irene Biraro [§]	2015-2016	Tuberculosis	MUII	Senior Lecturer, Department of Medicine, Makerere CHS
PhD Fellows, completed				

Forename	Award dates	Research area/focus	Funding	Current position
Rose Nabatanzi	2017-2019	Under Damalie Nakanjako's Group Leader Award	MUII-plus	Post-doc and MUII Immunology Impi leader
Nicholas Bbosa	2014-2017	HIV phylodynamics and phylogeography	MRC *	PhD student
Moses Egesa	2013-2017	B- and T-cell responses to novel <i>Schistosoma mansoni</i> skin-stage vaccine candidate antigens	MUII/MUII-plus	PhD student; Scientific Officer, UVRI
Swaib Lule	2016-2019	Fetal Origins of Disease	Common-wealth*	Post-doctoral research, University College London
Simon Kimuda	2013-2017	Effects of <i>Mycobacterium tuberculosis</i> on B cell responses	MUII/ MUII-plus	Project leader and post-doctoral fellow, MRC/UVRI & LSHTM Uganda Research Unit
Annettee Nakimuli	2009-2013	The Role of Natural Killer Cells in Preeclampsia in an African population: A genetic study of Killer immunoglobulin-like receptors and HLA-C polymorphisms	MUII	Head of Department of Obstetrics & Gynaecology, Makerere CHS
Agnes Kiragga	2009-2013	Improving prediction of HIV outcomes using from routine Observational data using nested research cohort databases	MUII	Head of Statistics, Infectious Diseases Institute, Makerere CHS
John Kitayimbwa	2009-2013	Viral dynamics of HIV during combinational therapy amidst emergence of HIV drug resistant strains	MUII	Lecturer, Department of Mathematics, Makerere CONAS
Irene Biraro	2009-2013	Co-infections and their role in altering immune responses in household contacts exposed to sputum positive tuberculosis in Uganda	MUII	Senior Lecturer, Department of Medicine, Makerere CHS
Masters fellows, completed				
Frances Ramatu Wurie	2018-2019	MMED: exploration of mycobacterium Tuberculosis antigen specific iga in saliva of subjects with latent and active TB	MUII-plus	Masters student
Beatrice Nassanga	2016-2018	Immunology & Clinical Microbiology. Project: Immunological factors affecting the immune response to TB vaccine candidate MVA85A	MUII-plus	Masters student
Alex Kayongo	2016-2018	Immunology & Clinical Microbiology. Project: Host genetic factors responsible for CD4 intrinsic resistance to HIV in Ugandan Elite and viraemic controllers	MUII-plus	Masters student
Lilian Namuli	2016-2018	Immunology & Clinical Microbiology: project to be decided	MUII-plus	Masters student
Emmanuella Dricuru	2016-2018	Immunology & Clinical Microbiology: project to be decided	MUII-plus	Masters student
Paul Katongole	2017-2018	Biofilm Formation in uropathogenic <i>Escherichia coli</i>	MUII-plus	Masters student (project funding)

Forename	Award dates	Research area/focus	Funding	Current position
		strains in Uganda: relationship with urovirulence factors and antimicrobial resistance		
Grace Nabakooza	2016-2018	Bioinformatics	MUII-plus	Masters student
Alfred Ssekagiri	2016-2018	Bioinformatics	MUII-plus	Masters student
Simon Kimuda	2011-2013	Immunology & Clinical Microbiology	MUII	PhD student, MUII
Peter Naniima	2011-2013	Molecular Biology	MUII	PhD student, Hannover, Germany
Doreen Tuhebwe	2011-2013	Public Health	MUII	Project coordinator, Institute of Public Health, Makerere
Justine Bukirwa	2011-2013	Immunology & Clinical Microbiology	MUII	Infectious Diseases Institute
Harriet Namanya	2011-2013	Immunology & Clinical Microbiology	EU*	
Moses Egesa	2011-2013	Immunology & Clinical Microbiology	EU*	PhD student, MUII

* Honorary MUII fellows – trainees participating in the MUII fellowship programme but supported by other funding sources[§]
One year, post-doctoral bridging funds